HILL-ROM HOLDINGS, INC., 10-Q filed on 7/30/2021
Quarterly Report
v3.21.2
Document and Entity Information - shares
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Jul. 28, 2021
Document And Entity Information Abstract      
Document Type   10-Q  
Title of 12(b) Security   Common Stock, without par value  
Entity Shell Company   false  
Entity Interactive Data Current Yes    
Document Quarterly Report   true  
Document Period End Date   Jun. 30, 2021  
Document Transition Report   false  
Entity File Number   1-6651  
Entity Registrant Name   HILL-ROM HOLDINGS, INC.  
Entity Incorporation, State or Country Code   IN  
Entity Tax Identification Number   35-1160484  
Entity Address, State or Province   IL  
Entity Address, City or Town   Chicago  
Entity Address, Postal Zip Code   60601  
Trading Symbol   HRC  
Security Exchange Name   NYSE  
Amendment Flag   false  
Entity Central Index Key   0000047518  
Current Fiscal Year End Date   --09-30  
Document Fiscal Year Focus   2021  
Document Fiscal Period Focus   Q3  
Entity Filer Category   Large Accelerated Filer  
Entity Common Stock, Shares Outstanding     65,816,571
Entity Emerging Growth Company   false  
Entity Small Business   false  
Document Information [Line Items]      
Entity Voluntary Filers   Yes  
Entity Interactive Data Current Yes    
Entity Shell Company   false  
v3.21.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Product sales and service revenue $ 635,500,000 $ 685,800,000 $ 1,956,500,000 $ 1,947,100,000
Rental revenue 82,200,000 81,700,000 264,300,000 228,600,000
Revenues 717,700,000 767,500,000 2,220,800,000 2,175,700,000
Total cost of net revenue (excludes acquisition-related intangible asset amortization) 306,600,000 323,100,000 948,900,000 946,600,000
Rental expenses 36,600,000 35,400,000 110,800,000 110,900,000
Cost of Revenue 343,200,000 358,500,000 1,059,700,000 1,057,500,000
Research and development expenses 36,300,000 34,400,000 105,600,000 100,300,000
Selling and administrative expenses 215,900,000 202,300,000 648,600,000  
Amortization of Intangible Assets 27,000,000.0 27,500,000 80,700,000 81,300,000
Special charges 5,900,000 9,500,000 40,100,000 26,100,000
Operating Profit 89,400,000 135,300,000 286,100,000 301,500,000
Interest expense (15,700,000) (17,300,000) (50,600,000) (55,800,000)
Gain (Loss) on Extinguishment of Debt (9,800,000) 0 (9,800,000) (15,600,000)
Investment income (expense) and other, net (3,400,000) 2,200,000 12,700,000 (10,500,000)
Income Before Income Taxes 60,500,000 120,200,000 238,400,000 219,600,000
Income Tax Expense (Benefit) 11,300,000 26,300,000 43,300,000 39,000,000.0
Net Income $ 49,200,000 $ 93,900,000 $ 195,100,000 $ 180,600,000
Net Income Attributable to Common Shareholders per Common Share - Basic (usd per share) $ 0.74 $ 1.41 $ 2.94 $ 2.71
Earnings Per Share, Diluted $ 0.74 $ 1.40 $ 2.92 $ 2.68
Average Common Shares Outstanding - Basic (thousands) (Note 10) (in shares) 66,267 66,558 66,353 66,660
Average Common Shares Outstanding - Diluted (thousands) (Note 10) (in shares) 66,841 67,183 66,869 67,292
v3.21.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net Income $ 49,200,000 $ 93,900,000 $ 195,100,000  
Other Comprehensive (Loss) Income, net of tax (Note 7):        
Derivative instruments designated as hedges 1,200,000 (6,700,000) 11,700,000 $ (32,400,000)
Foreign currency translation adjustment 11,700,000 17,100,000 26,500,000 8,600,000
Change in pension and postretirement defined benefit plans 800,000 1,000,000.0 (2,500,000) 5,900,000
Other Comprehensive Income (Loss), Net of Tax, Total 13,700,000 11,400,000 40,700,000 (29,700,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $ 62,900,000 $ 105,300,000 $ 235,800,000 $ 150,900,000
v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Jun. 30, 2021
Sep. 30, 2020
Current Assets    
Cash and cash equivalents $ 272,500,000 $ 296,500,000
Trade accounts receivable, net of allowances of $23.7 and $25.9 as of June 30, 2021 and September 30, 2020 575,900,000 594,900,000
Inventory, Net 329,100,000 352,000,000.0
Other current assets 128,700,000 121,500,000
Total current assets 1,306,200,000 1,364,900,000
Property, plant and equipment 877,400,000 858,200,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment (583,700,000) (552,100,000)
Property, Plant and Equipment, Net 293,700,000 306,100,000
Goodwill 1,845,600,000 1,835,500,000
Other intangible assets and software, net 965,000,000.0 976,700,000
Deferred Income Tax Assets, Net 33,600,000 32,900,000
Other assets 128,600,000 155,000,000.0
Assets 4,572,700,000 4,671,100,000
Current Liabilities    
Trade accounts payable 219,000,000.0 236,500,000
Short-term borrowings 238,400,000 222,300,000
Accrued compensation 164,400,000 144,900,000
Accrued product warranties 30,200,000 30,800,000
Accrued rebates 47,400,000 44,800,000
Deferred Revenue 108,600,000 110,100,000
Other current liabilities 137,700,000 162,800,000
Total current liabilities 945,700,000 952,200,000
Long-term debt 1,482,200,000 1,655,700,000
Accrued pension and postretirement benefits 93,800,000 89,300,000
Deferred Income Tax Liabilities, Net 110,700,000 113,000,000.0
Other long-term liabilities 119,300,000 134,800,000
Total Liabilities 2,751,700,000 2,945,000,000.0
SHAREHOLDERS' EQUITY    
Common Stock, Value, Issued 4,400,000 4,400,000
Additional paid-in capital 694,200,000 667,000,000.0
Retained earnings 2,278,400,000 2,132,200,000
Accumulated other comprehensive (loss) (139,500,000) (180,200,000)
Treasury stock, common shares at cost: 22,663,241 as of June 30, 2021 and 21,816,802 as of September 30, 2020 (1,016,500,000) (897,300,000)
Total Shareholders’ Equity 1,821,000,000.0 1,726,100,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 1,821,000,000.0 1,726,100,000
Total Liabilities and Shareholders' Equity 4,572,700,000 4,671,100,000
Allowance for possible losses and discounts on trade receivables $ 23.7 $ 25.9
Shares authorized 1,000,000  
Common Stock, Shares Authorized 199,000,000  
Common Stock, Shares, Issued 88,457,634  
Common Stock, Shares, Outstanding 65,794,393 66,640,832
Treasury Stock, Common, Shares 22,663,241 21,816,802
Liabilities and Equity $ 4,572,700,000 $ 4,671,100,000
v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating Activities    
Net Income (Loss) Attributable to Parent $ 195,100,000 $ 180,600,000
Adjustments to reconcile net income to net cash, cash equivalents and restricted cash provided by operating activities:    
Depreciation and Amortization of PP&E and Software 56,900,000 51,600,000
Acquisition-related intangible asset amortization 80,700,000 81,300,000
Amortization of Debt Issuance Costs and Discounts 2,800,000 3,000,000.0
Gain (Loss) on Extinguishment of Debt 9,800,000 15,600,000
Benefit for deferred income taxes (6,800,000) (14,100,000)
Loss on disposal of property, equipment, intangible assets and impairments 300,000 1,500,000
Stock compensation 32,700,000 27,200,000
Other Operating Activities, Cash Flow Statement 14,600,000 16,000,000.0
Change in working capital excluding cash, current debt, acquisitions and dispositions:    
Trade accounts receivable (20,900,000) (12,300,000)
Inventories (12,400,000) 60,200,000
Other current assets 6,800,000 10,400,000
Trade accounts payable (10,100,000) 16,500,000
Accrued expenses and other liabilities 19,400,000 (8,100,000)
Increase (Decrease) in Accounts Receivable 20,900,000 12,300,000
Increase (Decrease) in Inventories 12,400,000 (60,200,000)
Increase (Decrease) in Other Operating Assets (6,800,000) (10,400,000)
Increase (Decrease) in Accounts Payable, Trade (10,100,000) 16,500,000
Accrued expenses and other liabilities 19,400,000 (8,100,000)
Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net (11,500,000) 2,000,000.0
Net Cash Provided by (Used in) Operating Activities, Total 410,400,000 314,800,000
Investing Activities    
Purchases of property, plant, equipment and software (69,000,000.0) (72,000,000.0)
Proceeds on sale of property and equipment 2,400,000 1,600,000
Payments to Acquire Businesses, Gross (30,000,000.0) (20,600,000)
Other investing activities 0 (600,000)
Net Cash Provided by (Used in) Investing Activities (96,600,000) (90,400,000)
Financing Activities    
Repayments of Long-term Debt (37,600,000) (37,600,000)
Borrowings on Revolving Credit Facility 475,000,000.0 (190,000,000.0)
Payments on Revolving Credit Facility (315,000,000.0) (155,000,000.0)
Borrowings on Securitization Facility 46,100,000 17,700,000
Payments on Securitization Facility (30,000,000.0) (17,700,000)
Principal Amount Outstanding on Loans Securitized or Asset-backed Financing Arrangement 90,000,000.0 32,600,000
Payments on Note Securitization Facility (90,000,000.0) (21,200,000)
Payment for Debt Extinguishment or Debt Prepayment Cost (7,500,000) (12,200,000)
Early Repayment of Senior Debt (300,000,000.0) (425,000,000.0)
Cash dividends (46,300,000) (43,300,000)
Proceeds on exercise of stock options 8,100,000 8,500,000
Payment, Tax Withholding, Share-based Payment Arrangement (9,300,000) (16,400,000)
Payments for Repurchase of Common Stock (130,700,000) (54,100,000)
Proceeds from (Payments for) Other Financing Activities 5,000,000.0 6,000,000.0
Net Cash Provided by (Used in) Financing Activities, Total (342,200,000) (527,700,000)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 4,400,000 1,300,000
Net Cash Flows (24,000,000.0) (302,000,000.0)
Cash, Cash Equivalents and Restricted Cash:    
At beginning of period 296,500,000 633,800,000
At end of period $ 272,500,000 $ 331,800,000
v3.21.2
Condensed Consolidated Statements of Shareholders' Equity (unaudited) Statement - USD ($)
Total
Previously Reported
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2019     88,457,634        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Sep. 30, 2019 $ 1,573,300,000   $ 4,400,000     $ (182,500,000) $ (853,400,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
New Accounting Standard Adjustment | Accounting Standards Update 2016-13 [Member]         $ 100,000    
Net Income (Loss) Attributable to Parent 180,600,000       180,600,000    
Other Comprehensive Income (Loss), Net of Tax (29,700,000)         (29,700,000)  
Dividends (43,300,000)     $ 400,000 (43,700,000)    
Payment, Tax Withholding, Share-based Payment Arrangement (16,400,000)           (16,400,000)
Payments for Repurchase of Common Stock (54,100,000)           (54,100,000)
Share-based Payment Arrangement, Increase for Cost Recognition 26,400,000     26,400,000      
Stock Issued During Period, Value, Stock Options Exercised (8,500,000)     (2,900,000)     (5,600,000)
Stock Issued During Period, Value 0     (16,900,000)     16,900,000
Stock Issued During Period, Value, Employee Stock Purchase Plan 6,800,000     4,200,000     2,600,000
Other Comprehensive Income (Loss), Tax           11,400,000  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2020 1,652,400,000   $ 4,400,000 654,400,000 2,104,600,000 (212,200,000) (898,800,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance (Retained Earnings [Member]) at Jun. 30, 2020   $ 300,000          
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2019     88,457,634        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Sep. 30, 2019 1,573,300,000   $ 4,400,000     (182,500,000) (853,400,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Other Comprehensive Income (Loss), Net of Tax $ (29,700,000)            
Common Stock, Dividends, Per Share, Cash Paid $ 0.65            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2020 $ 1,726,100,000   $ 4,400,000 667,000,000.0 2,132,200,000 (180,200,000) (897,300,000)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2020     88,457,634        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2020 1,548,900,000   $ 4,400,000 644,400,000 2,025,200,000 (223,600,000) (901,500,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
New Accounting Standard Adjustment | Accounting Standards Update 2016-13 [Member]         800,000    
Net Income (Loss) Attributable to Parent 93,900,000       93,900,000    
Other Comprehensive Income (Loss), Net of Tax 11,400,000         11,400,000  
Dividends (14,600,000)     200,000 (14,800,000)    
Payment, Tax Withholding, Share-based Payment Arrangement (600,000)           (600,000)
Share-based Payment Arrangement, Increase for Cost Recognition 7,900,000     7,900,000      
Stock Issued During Period, Value, Stock Options Exercised (2,800,000)     (1,200,000)     (1,600,000)
Stock Issued During Period, Value (100,000)     (800,000)     700,000
Stock Issued During Period, Value, Employee Stock Purchase Plan 2,500,000     1,500,000     1,000,000.0
Other Comprehensive Income (Loss), Tax           1,600,000  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2020 $ 1,652,400,000   $ 4,400,000 654,400,000 2,104,600,000 (212,200,000) (898,800,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance (Retained Earnings [Member]) at Jun. 30, 2020   300,000          
Common Stock, Shares, Outstanding, Beginning Balance at Jun. 30, 2020     88,457,634        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Common Stock, Dividends, Per Share, Cash Paid $ 0.22            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Sep. 30, 2020 $ 1,726,100,000   $ 4,400,000 667,000,000.0 2,132,200,000 (180,200,000) (897,300,000)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2020 66,640,832   88,457,634        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income (Loss) Attributable to Parent $ 195,100,000       195,100,000    
Other Comprehensive Income (Loss), Net of Tax 40,700,000         40,700,000  
Dividends (46,300,000)     400,000 (46,700,000)    
Payment, Tax Withholding, Share-based Payment Arrangement (9,300,000)           (9,300,000)
Payments for Repurchase of Common Stock (130,700,000)           (130,700,000)
Share-based Payment Arrangement, Increase for Cost Recognition 32,000,000.0     32,000,000.0      
Stock Issued During Period, Value, Stock Options Exercised (8,100,000)     (2,600,000)     (5,500,000)
Stock Issued During Period, Value 0     (12,300,000)     12,300,000
Stock Issued During Period, Value, Employee Stock Purchase Plan 7,500,000     4,500,000     3,000,000.0
Other Comprehensive Income (Loss), Tax           (4,500,000)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2021 $ 1,821,000,000.0 (2,200,000) $ 4,400,000 694,200,000 2,278,400,000 (139,500,000) (1,016,500,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance (Retained Earnings [Member]) at Jun. 30, 2021   (2,200,000)          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accounting Standards Update [Extensible List] Accounting Standards Update 2016-13 [Member]            
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021     88,457,634        
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2021 $ 1,839,700,000   $ 4,400,000 681,700,000 2,245,100,000 (153,200,000) (938,300,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income (Loss) Attributable to Parent 49,200,000       49,200,000    
Other Comprehensive Income (Loss), Net of Tax 13,700,000         13,700,000  
Dividends (15,800,000)     100,000 (15,900,000)    
Payment, Tax Withholding, Share-based Payment Arrangement (800,000)           (800,000)
Payments for Repurchase of Common Stock             (83,300,000)
Share-based Payment Arrangement, Increase for Cost Recognition 9,700,000     9,700,000      
Stock Issued During Period, Value, Stock Options Exercised (6,100,000)     (2,200,000)     (3,900,000)
Stock Issued During Period, Value 0     (1,100,000)     1,100,000
Stock Issued During Period, Value, Employee Stock Purchase Plan 2,500,000     1,600,000     900,000
Other Comprehensive Income (Loss), Tax           (800,000)  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2021 $ 1,821,000,000.0 (2,200,000) $ 4,400,000 $ 694,200,000 $ 2,278,400,000 $ (139,500,000) $ (1,016,500,000)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance (Retained Earnings [Member]) at Jun. 30, 2021   $ (2,200,000)          
v3.21.2
Summary of Significant Accounting Policies
 9 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Nature of Operations Hill-Rom Holdings, Inc. (the “Company,” “Hillrom,” “we,” “us,” or “our”) was incorporated on August 7, 1969, in the State of Indiana and is headquartered in Chicago, Illinois. We are a global medical technology leader whose approximately 10,000 employees have a single purpose: enhancing outcomes for patients and their caregivers by Advancing Connected Care™. Around the world, our innovations touch over 7 million patients each day. Our products and services help enable earlier diagnosis and treatment, optimize surgical efficiency and accelerate patient recovery while simplifying clinical communication and shifting care closer to home. We make these outcomes possible through digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, advanced equipment for the surgical space and more, delivering actionable, real-time insights at the point of care.
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation

The unaudited Condensed Consolidated Financial Statements and related notes have been prepared in accordance with the rules and regulations of the SEC for interim unaudited Condensed Consolidated Financial Statements. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete Condensed Consolidated Financial Statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying Condensed Consolidated Financial Statements to present fairly the results of the interim periods presented. Quarterly results are not necessarily indicative of annual results.

The unaudited Condensed Consolidated Financial Statements appearing in this Quarterly Report on Form 10-Q should be read in conjunction with the audited Condensed Consolidated Financial Statements and notes thereto included in Hillrom’s fiscal 2020 Form 10-K as filed with the SEC.

The Condensed Consolidated Financial Statements include the accounts of Hillrom and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

The Company makes a number of significant estimates, assumptions, and judgments in the preparation of its financial statements. Additionally, the Company measures and classifies fair value measurements in accordance with the level hierarchy in conformity with GAAP. As of June 30, 2021, the Company's significant accounting policies and estimates and valuation techniques used to measure fair value have not changed from September 30, 2020. See Note 1. Summary of Significant Accounting Policies within the 2020 Form 10-K for the fiscal year ended September 30, 2020 for further information.

Revenue Recognition — Sales and Rentals

Disaggregation of Revenue

The Company disaggregates revenue recognized from contracts with customers by geography and reportable segments consistent with the way in which management operates and views the business. See Note 11. Segment Reporting for the presentation of the Company's revenue disaggregation.

Contract Balances

Contract liabilities represent deferred revenues that arise as a result of cash received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. These contract liabilities are recorded in Deferred revenue and Other long-term liabilities. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within 12 to 24 months.
The nature of our products and services does not give rise to contract assets as we typically do not have instances where a right to payment for goods and services already transferred to a customer exists that is conditional on something other than the passage of time.

The following table summarizes contract liability activity for the nine months ended June 30, 2021. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Contract Liabilities
Balance as of September 30, 2020$138.1 
New revenue deferrals378.2 
Revenue recognized upon satisfaction of performance obligations(380.9)
Foreign currency translation adjustment0.8 
Balance as of June 30, 2021$136.2 

Rental Revenue

We make certain products available to customers under short-term lease arrangements. Rental usage of these products is provided as an alternative to product sales and is short-term in nature. Products primarily include smart beds, including, but not limited to, bariatric, intensive care unit, maternity, and home care beds, as well as surfaces. These lease arrangements provide our customers with our products during periods of peak demand or often times for specialty purposes. Additionally, we provide wearable, non-invasive ventilation products to patients covered by monthly medical insurance reimbursements, which are considered month-to-month leasing arrangements. Income arising from these lease arrangements where we are the lessor is recognized within Rental revenue. We accounted for these lease arrangements as operating leases.

Warranties and Guarantees

We routinely grant limited warranties on our products with respect to defects in material and workmanship. The terms of these warranties are generally one year; however, certain components and products have substantially longer warranty periods. We recognize a reserve with respect to these obligations at the time of product sale, with subsequent warranty claims recorded directly against the reserve. The amount of the warranty reserve is determined based on historical trend experience for the covered products. For more significant warranty-related matters, which might require a field corrective action, separate reserves are established when such events are identified and the cost of correction can be reasonably estimated.

In the normal course of business, we enter into various other guarantees and indemnities in our relationships with suppliers, service providers, customers, business partners and others. Examples of these arrangements would include guarantees of product performance, indemnifications to service providers and indemnifications of our actions to business partners. These guarantees and indemnifications have not historically had a material impact on our financial condition or results of operations, nor do we expect them to although indemnifications associated with our actions generally have no dollar limitations.

In conjunction with our acquisition and divestiture activities, we entered into select guarantees and indemnifications of performance with respect to the fulfillment of our commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. With respect to divestitures, we also routinely enter into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have an adverse impact on our Condensed Consolidated Financial Statements.
The following summarizes accrued product warranty activity for the three and nine months ended June 30, 2021.

  Three Months Ended June 30 Nine Months Ended June 30
Balance as of beginning of period$30.3 $30.8 
Provision for warranties in the period5.8 16.9 
Warranty claims in the period(6.0)(17.7)
Foreign currency translation adjustment0.1 0.2 
Balance as of end of period$30.2 $30.2 

Goodwill and Indefinite-Lived Intangible Assets

Testing for goodwill and indefinite-lived intangible asset impairment is performed annually, or on an interim basis upon the occurrence of a triggering event or change in circumstances that would more likely than not reduce the fair value of a reporting unit or indefinite-lived intangible asset below its carrying amount. The annual evaluations of goodwill and the indefinite-lived intangible asset for impairment were performed as of April 30, 2021 and did not result in any impairment.
Government Programs Related to COVID-19
On March 25, 2020, the U.S. government approved the Coronavirus Aid, Relief and Economic Security (“CARES”) Act to provide economic stimulus to address the impact of the pandemic. The governments in certain other non-U.S. countries have also approved legislation in their jurisdictions to address the impact of the pandemic. We evaluated our eligibility and assessed the conditions and requirements of participation in available programs. During the calendar year 2020, we deferred payment of the employer share of the U.S. Federal Insurance Contributions Act (“FICA”) taxes totaling $21.7 million within the Condensed Consolidated Balance Sheet, of which $10.8 million must be repaid in both December 31, 2021 and December 31, 2022, respectively, in accordance with the CARES Act within the Condensed Consolidated Balance Sheet. We continue to evaluate what impact, if any, the CARES Act, or any similar legislation in other non-U.S. jurisdictions, may have on our results of operations.
v3.21.2
Supplementary Balance Sheet Information
 9 Months Ended
Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Supplementary Balance Sheet Information Supplementary Financial Statement Information
 June 30,
2021		September 30, 2020
Inventories, net of reserves:  
Finished products$160.0 $167.6 
Work in process53.1 48.4 
Raw materials116.0 136.0 
Total inventories, net of reserves$329.1 $352.0 
Accumulated amortization of software and other intangible assets$762.6 $667.3 
Investments included in Other assets$23.7 $49.0 

Supplemental Cash Flow Information
Nine Months Ended
June 30
20212020
Non-cash operating activities:
Operating cash flows paid for amounts included in the measurement of lease liabilities$20.4$20.8 
Non-cash investing activities:
Change in capital expenditures not paid$(10.0)$1.8 
Sale of equity method investment— 2.1 
Non-cash consideration in exchange for asset acquisition:
Preferred securities investment25.5 — 
     Forgiveness of a prepaid performance obligation 1.8 — 
Total non-cash investing activities:$17.3 $3.9 
Non-cash financing activities:  
Distribution of shares issued under stock-based compensation plans$36.9$29.6 
Non-cash investing and financing activities:
Right of use assets obtained in exchange for new lease liabilities$7.6$14.7 
v3.21.2
Acquisitions
 9 Months Ended
Jun. 30, 2021
Business Combinations [Abstract]  
Acquisitions Business Combinations
Acquisitions

Assets acquired and liabilities assumed in a business combination are recorded at their estimated fair values on the date of acquisition. The difference between the purchase price amount and the net fair value of assets acquired and liabilities assumed is recognized as goodwill on the balance sheet if the purchase price exceeds the estimated net fair value or as a bargain purchase gain on the income statement if the purchase price is less than the estimated net fair value. The allocation of the purchase price may be modified up to one year after the acquisition date as more information is obtained about the fair value of assets acquired and liabilities assumed.
During fiscal 2020 we acquired the following companies:
Company NameDescription of the BusinessDescription of the Acquisition
Excel MedicalClinical communications software company located in the United StatesPurchased all of the outstanding equity interest.
ConnectaClinical communications software company based in Mexico.Purchased the multiplatform medical device integration and connectivity software programs, products, and solutions of the company.
Videomed Developer of integrated video solutions in operating rooms located in Italy.Purchased all of the outstanding equity interest.

The purchase price for the acquisitions listed above includes contingent consideration for which the performance periods have not yet expired. For the nine months ended June 30, 2021, we recorded a reduction in the contingent consideration obligations of $2.6 million, in Selling and administrative expenses primarily related to Excel Medical as a certain commercial milestone was not met. During the three and nine months ended June 30, 2021, we paid $2.0 million in cash as contingent consideration associated with the acquisition of Excel Medical. As of June 30, 2021 and September 30, 2020, contingent consideration liabilities related to prior year acquisitions totaled $4.3 million and $8.9 million and are included in Other current liabilities and Other long-term liabilities.

For the nine months ended June 30, 2021, we did not close on any new business acquisitions. For additional information on Acquisitions, see Note 3. Business Combinations within the 2020 Form 10-K.

Bardy Diagnostics, Inc.

On January 15, 2021, Hill-Rom, Inc., our wholly owned subsidiary, entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among Hill-Rom, Inc., Barcelona Merger Sub, Inc. (“Merger Sub”), Bardy Diagnostics, Inc. (“Bardy”) and Fortis Advisors LLC (as Equityholders’ Representative), providing for our acquisition of Bardy. Pursuant to the terms of the Merger Agreement, Merger Sub will be merged with and into Bardy with Bardy surviving the merger as our wholly owned subsidiary. The Merger Agreement provides that holders of outstanding shares of Bardy common and preferred stock and holders of Bardy warrants, stock options and other equity-related awards will be entitled to receive initial cash consideration of $375.0 million, subject to closing conditions and certain post-closing adjustments (the “Bardy Transaction”). Additional contingent cash consideration will be payable based on the revenue generated from the acquired cardiac monitoring product during the first two calendar years starting with the calendar year in which the transaction is closed.

The contingent consideration payable for the first calendar year in which the transaction closes will equal (i) 50% of the revenue generated if less than $45.0 million, (ii) 100% of the revenue generated if such revenue is between $45.0 million and $57.0 million, and (iii) 150% of revenue generated if greater than $57.0 million during calendar year 2021.

The contingent consideration payable for the second calendar year will equal (i) 50% of the revenue generated if such revenue is less than $70.0 million, (ii) 100% of the revenue generated if such revenue is between $70.0 million and $89.0 million, and (iii) 125% of the revenue generated if such revenue is greater than $89.0 million during the calendar year 2022.

On January 29, 2021, the Medicare Administrative Contractor, Novitas Solutions ("Novitas"), published newly established, Category 1 reimbursement rates applicable to the Current Procedural Terminology ("CPT") codes 93241, 93243, 93245 and 93247 for the extended holter cardiac monitoring category.

As a result of the unexpected Novitas reimbursement rate reduction, on February 21, 2021, Hillrom asserted that a "Company Material Adverse Effect" occurred, and therefore the closing conditions were not satisfied. On February 28, 2021, Bardy filed a complaint against Hillrom in the Court of Chancery of the State of Delaware seeking, among other things, specific performance to compel Hillrom to close the transaction.

On April 10, 2021, Novitas published updated reimbursement rates applicable to CPT codes 93241, 93243, 93245 and 93247 and Hillrom reconfirmed its position that a “Company Material Adverse Effect” occurred.
Following a trial conducted during May 5-7, 2021, on July 9, 2021, the Court of Chancery of the State of Delaware ordered Hillrom to proceed with the closing of the Bardy Transaction, denying Hillrom’s claim of a "Company Material Adverse Effect". Hillrom now anticipates closing of the Bardy Transaction on or about August 6, 2021.
Asset Acquisition

On January 28, 2021, we acquired the contact-free continuous monitoring intellectual property and technology from EarlySense Ltd. in exchange for cash of $30.0 million, a portion of our non-marketable equity investment in EarlySense Ltd. of $25.5 million at cost and forgiveness of a prepayment of approximately $1.8 million. The investment was transferred to EarlySense Ltd. on April 27, 2021 after certain conditions outlined in the purchase agreement were satisfied. Additionally, contingent consideration of up to $10.0 million will be payable if commercial milestones defined in the purchase agreement are achieved through September 2023.
The value of the acquired intangible asset recorded upon close of the transaction was $59.4 million, which included estimated contingent consideration of $2.4 million. The intangible asset acquired is presented in Other intangible assets and software, net and is amortized over the expected useful life of the technology of 8 years. The liability for the contingent consideration is included in Other long-term liabilities. Revenues generated from this asset acquisition are recorded within the Patient Support Systems segment.
v3.21.2
Financing Agreements
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Debt Disclosure [Abstract]    
Financing Agreements   Financing Agreements
Short-Term Borrowings

Securitization Facilities

On April 23, 2021, we renewed our 364-day accounts receivable securitization program (the " Securitization Facility ") with certain financial institutions for borrowings up to $110.0 million. Additionally, we renewed our 364-day facility for borrowings up to $90.0 million (the "Note Securitization Facility") on April 23, 2021. The terms and conditions of the renewed April 2021 facilities are substantially similar to the expired April 2020 facilities. As of June 30, 2021, outstanding borrowings were $98.3 million on the Securitization Facility and $90.0 million on the Note Securitization Facility. As of September 30, 2020, outstanding borrowings were $82.2 million on the Securitization Facility and $90.0 million on the Note Securitization Facility. Borrowings outstanding under the renewed Securitization Facility and renewed Note Securitization Facility bear interest at LIBOR plus the applicable margin of 0.78% and 0.85%.

Long-Term Debt

As of June 30, 2021, there were $160.0 million outstanding borrowings on the Revolving Credit Facility and available borrowing capacity was $1,030.0 million after giving effect to the outstanding standby letters of credit $10.0 million. As of September 30, 2020, there were no outstanding borrowings on the Revolving Credit Facility, and available borrowing capacity was $1,191.0 million after giving effect to $9.0 million of outstanding standby letters of credit.

Long-Term Debt Redemptions

On May 20, 2021, we redeemed the senior unsecured 5.00% notes due February 15, 2025 for $300.0 million using cash on hand and funds borrowed from both Securitization Facilities and the Revolving Credit Facility. For the three and nine months ended June 30, 2021, we recorded a loss on extinguishment of debt of $9.8 million, which was comprised of a $7.5 million prepayment premium and $2.3 million of debt issuance costs previously capitalized.

On October 7, 2019, we redeemed the senior unsecured 5.75% notes due September 2023 for $425.0 million and paid the prepayment premium of $12.2 million using the net proceeds from the senior unsecured 4.375% notes of $425.0 million maturing September 2027 that were issued in September 2019, along with funds borrowed from the Revolving Credit Facility. For the nine months ended June 30, 2020, we recorded a loss on extinguishment of debt of $15.6 million, which was comprised of a $12.2 million prepayment premium and $3.4 million of debt issuance costs previously capitalized.

See Note 5. Financing Agreements included within our 2020 Form 10-K for the fiscal year ended September 30, 2020 for further information.


Fair Value

The fair value of our debt is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to us for debt of the same remaining maturities. The book values of our Securitization Facility, Note Securitization Facility, Term Loan A facility maturing in August 2024, and Revolving Credit Facility approximate fair value.

The estimated fair values of our long-term debt instruments are described in the table below:
 June 30,
2021		September 30, 2020
Senior unsecured 5.00% notes due on February 15, 2025
$— $310.1 
Senior unsecured 4.375% notes due on September 15, 2027
443.3 441.2 
Unsecured debentures47.2 48.0 
Total$490.5 $799.3 

The estimated fair values of our long-term unsecured debentures were based on observable inputs such as quoted prices in markets that are not active. The estimated fair values of the Senior Notes were based on quoted prices for similar liabilities. These fair value measurements were classified as Level 2.

Debt Covenants

As of June 30, 2021, we were in compliance with all debt covenants under our financing agreements.
Subsequent Events On May 20, 2021, we redeemed the senior unsecured 5.00% notes due February 15, 2025 for $300.0 million using cash on hand and funds borrowed from both Securitization Facilities and the Revolving Credit Facility. For the three and nine months ended June 30, 2021, we recorded a loss on extinguishment of debt of $9.8 million, which was comprised of a $7.5 million prepayment premium and $2.3 million of debt issuance costs previously capitalized.  
v3.21.2
Derivatives
 9 Months Ended
Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments and Hedging Activity
We are exposed to various market risks, including fluctuations in interest rates and variability in foreign currency exchange rates. We have established policies, procedures, and internal processes governing our management of market risks and the use of financial instruments to manage our exposure to such risks. We employ cash flow hedges, net investment hedges, and other derivative instruments not designated for hedge accounting to manage these risks.

Cash Flow Hedges

To manage our exposure to market risk from fluctuations in interest rates, we enter into interest rate swaps that are designated as cash flow hedges. As of June 30, 2021 and September 30, 2020, we had interest rate swap agreements with an aggregate notional amount of $750.0 million to hedge the variability of cash flows through August 2024 associated with a portion of the variable interest rate payments on outstanding borrowings under our Senior Credit Agreement.

We are subject to variability in foreign currency exchange rates due to our international operations. We enter into currency exchange contracts that are designated as cash flow hedges to manage our exposure arising from fluctuating exchange rates related to specific and projected transactions. We operate this program pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. The sensitivity of earnings and cash flows to variability in exchange rates is assessed by applying an appropriate range of potential rate fluctuations to our assets, obligations, and projected results of operations denominated in foreign currencies. Our currency risk consists primarily of foreign currency denominated firm commitments and projected foreign currency denominated intercompany and third-party transactions. As of June 30, 2021 and September 30, 2020, the notional amount of outstanding currency exchange contracts was $8.1 million and $64.4 million, respectively. The maximum length of time over which we hedge transaction exposures is generally 12 months. Derivative gains and losses, initially reported as a component of Accumulated other comprehensive income (loss), are reclassified to earnings in the period when the underlying transaction affects earnings.

Net Investment Hedges

As of June 30, 2021 and September 30, 2020, we had cross-currency swap agreements, with an aggregate notional amount of $198.3 million, to hedge the variability of net assets due to changes in the U.S. dollar-Euro spot exchange rates through July 2023. These cross-currency swaps are designated as net investment hedges of subsidiaries using the Euro as their functional currency. 
We assess hedge effectiveness under the spot-to-spot method and record changes in fair value attributable to the translation of foreign currencies through Accumulated other comprehensive income (loss). We amortize the impact of all other changes in fair value of the derivatives through Interest expense, which was income of $1.3 million and $3.9 million for both the three and nine months ended June 30, 2021 and 2020.

Undesignated Derivative Instruments

We use forward contracts to mitigate the foreign exchange revaluation risk associated with recorded monetary assets and liabilities that are denominated in a non-functional currency. These derivative instruments are not formally designated as hedges and the terms of these instruments generally do not exceed one month. As of June 30, 2021 and September 30, 2020, we had forward contracts not designated as hedges with aggregate notional amounts of $236.2 million and $169.9 million.

The following table summarizes unrealized and realized gains and losses for forward contracts not designated as hedges, which are recorded in Investment income (expense) and other, net.
Three Months Ended
June 30		Nine Months Ended
June 30
2021202020212020
Unrealized gain (loss)$(3.0)$0.5 $(3.0)$0.5 
Realized gain (loss)0.2 (0.1)(1.0)1.1 

Fair Value

We classify fair value measurements on our derivative instruments as Level 2. The estimated fair values of our derivative instruments are described in the table below:
Derivative InstrumentsJune 30, 2021September 30, 2020Condensed Consolidated Balance Sheet Position
Interest Rate Swaps$(25.9)$(46.3)Other current liabilities
Currency Exchange Contracts(0.6)(0.4)Other current liabilities
Cross-Currency Swaps6.0 9.7 Other assets
Undesignated Forward Contracts(3.7)— Other current liabilities
Undesignated Forward Contracts0.7 — Other assets
Total$(23.5)$(37.0)
v3.21.2
Retirement and Postretirement Plans
 9 Months Ended
Jun. 30, 2021
Retirement Benefits [Abstract]  
Compensation and Employee Benefit Plans Retirement and Postretirement Benefit Plans We sponsor five defined benefit retirement plans. Those plans include a master defined benefit retirement plan in the United States, a nonqualified supplemental executive defined benefit retirement plan, and three defined benefit retirement plans covering employees in Germany and France. Benefits for such plans are based primarily on years of service and the employee’s level of compensation in specific periods of employment. We contribute funds to trusts as necessary to provide for current service and for any unfunded projected future benefit obligation over a reasonable period of time. All of our plans have a September 30 measurement date. The following table provides the components of net pension expense for our defined benefit retirement plans.
 Three Months Ended
June 30		Nine Months Ended
June 30		Condensed Consolidated Statements of Income Item
 2021202020212020
Service cost$0.5 $0.5 $1.5 $1.3 Cost of goods sold
Service cost0.8 0.9 2.4 2.5 Selling and administrative expenses
Interest cost1.8 1.9 5.5 6.8 Investment income (expense) and other, net
Expected return on plan assets(2.9)(3.4)(8.8)(10.8)Investment income (expense) and other, net
Amortization of unrecognized prior service cost, net— — — 0.1 Investment income (expense) and other, net
Amortization of net loss1.6 1.9 4.7 5.0 Investment income (expense) and other, net
Net periodic benefit cost$1.8 $1.8 $5.3 $4.9 
Special termination benefits1
— — 3.3 — Special charges
Settlement (loss) gain2
— (0.1)— 8.4 Investment income (expense) and other, net
Net pension expense$1.8 $1.7 $8.6 $13.3 
1 In September 2020, we offered certain employees in the United States the option to participate in a voluntary early retirement plan. The employees who accepted the offer received special termination benefits during the nine months ended June 30, 2021, which were recorded as a component of Special charges in the Condensed Consolidated Statements of Income. See Note 8. Special Charges for further information.
2 On March 9, 2020, we transferred pension assets totaling $40.6 million to purchase annuity contracts for a certain population of retirees with a third-party insurance company. As a result, we recognized a non-cash settlement loss of $8.4 million for the for the nine months ended June 30, 2020, which is recorded as a component of Investment income (expense) and other, net in the Condensed Consolidated Statements of Income.

In addition to defined benefit retirement plans, we also offer two postretirement health care plans in the United States that provide health care benefits to qualified retirees and their dependents. The plans are closed to new participants and include retiree cost sharing provisions and generally extend retiree coverage for medical and prescription benefits beyond the COBRA continuation period to the date of Medicare eligibility. Annual costs related to these plans are not significant. In connection with the voluntary early retirement plan offered in September 2020, we incurred $0.2 million of special termination benefits related to our postretirement health care plan during the nine months ended June 30, 2021. The amount was recorded as a recorded as a component of Special charges in the Condensed Consolidated Statements of Income. See Note 8. Special Charges for further information.

We have defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security in retirement by providing employees with an incentive to regularly save a portion of their earnings. Our contributions to the plans are based on eligibility and, in some cases, employee contributions. Expense under these plans was $7.3 million and $23.1 million for the three and nine months ended June 30, 2021 and $7.3 million and $23.6 million for the three and nine months ended June 30, 2020.
v3.21.2
Other Comprehensive Income (Loss)
 9 Months Ended
Jun. 30, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
The following tables represent the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the three months ended June 30, 2021 and 2020:
Three Months Ended June 30, 2021
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance 2
Derivative instruments designated as hedges 1:
Currency exchange contracts
$2.2 $(1.2)$1.0 $(0.3)$0.7 $(1.2)$0.7 $(0.5)
Interest rate swaps
7.4 (4.0)3.4 (0.8)2.6 (22.5)2.6 (19.9)
Cross-currency swaps
(2.7)— (2.7)0.6 (2.1)4.9 (2.1)2.8 
Derivative instruments designated as hedges total
$6.9 $(5.2)$1.7 $(0.5)$1.2 $(18.8)$1.2 $(17.6)
Foreign currency translation adjustment
11.7 — 11.7 — 11.7 (95.9)11.7 (84.2)
Change in pension and postretirement defined benefit plans
(0.1)1.2 1.1 (0.3)0.8 (38.5)0.8 (37.7)
Total$18.5 $(4.0)$14.5 $(0.8)$13.7 $(153.2)$13.7 $(139.5)


Three Months Ended June 30, 2020
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance
Derivative instruments designated as hedges 1:
Currency exchange contracts
$0.4 $(1.2)$(0.8)$0.2 $(0.6)$— $(0.6)$(0.6)
Interest rate swaps
(2.9)(1.7)(4.6)1.1 (3.5)(34.8)(3.5)(38.3)
Cross-currency swaps
(3.5)— (3.5)0.9 (2.6)16.3 (2.6)13.7 
Derivative instruments designated as hedges total
$(6.0)$(2.9)$(8.9)$2.2 $(6.7)$(18.5)$(6.7)$(25.2)
Foreign currency translation adjustment
17.1 — 17.1 — 17.1 (153.9)17.1 (136.8)
Change in pension and postretirement defined benefit plans
0.2 1.4 1.6 (0.6)1.0 (51.2)1.0 (50.2)
Total$11.3 $(1.5)$9.8 $1.6 $11.4 $(223.6)$11.4 $(212.2)
The following tables represent the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the nine months ended June 30, 2021 and 2020.
Nine Months Ended June 30, 2021
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance 2
Derivative instruments designated as hedges 1:
Currency exchange contracts
$2.8 $(3.0)$(0.2)$— $(0.2)$(0.3)$(0.2)$(0.5)
Interest rate swaps
31.2 (10.7)20.5 (4.7)15.8 (35.7)15.8 (19.9)
Cross-currency swaps
(5.0)— (5.0)1.1 (3.9)6.7 (3.9)2.8 
Derivative instruments designated as hedges total
$29.0 $(13.7)$15.3 $(3.6)$11.7 $(29.3)$11.7 $(17.6)
Foreign currency translation adjustment
26.5 — 26.5 — 26.5 (110.7)26.5 (84.2)
Change in pension and postretirement defined benefit plans
(0.3)3.7 3.4 (0.9)2.5 (40.2)2.5 (37.7)
Total$55.2 $(10.0)$45.2 $(4.5)$40.7 $(180.2)$40.7 $(139.5)

Nine Months Ended June 30, 2020
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance
Derivative instruments designated as hedges 1:
Currency exchange contracts
$0.1 $(1.1)$(1.0)$0.2 $(0.8)$0.2 $(0.8)$(0.6)
Interest rate swaps
(41.7)(1.3)(43.0)9.9 (33.1)(5.2)(33.1)(38.3)
Cross-currency swaps
1.9 — 1.9 (0.4)1.5 12.2 1.5 13.7 
Derivative instruments designated as hedges total
$(39.7)$(2.4)$(42.1)$9.7 $(32.4)$7.2 $(32.4)$(25.2)
Foreign currency translation adjustment
8.6 — 8.6 — 8.6 (145.4)8.6 (136.8)
Change in pension and postretirement defined benefit plans
0.1 (7.7)(7.6)1.7 (5.9)(44.3)(5.9)(50.2)
Total$(31.0)$(10.1)$(41.1)$11.4 $(29.7)$(182.5)$(29.7)$(212.2)


1 See Note 5. Derivative Instruments and Hedging Activity for information regarding our hedging strategies.
2 The estimated net amount of gains and losses reported in Accumulated other comprehensive income (loss) related to our derivative instruments designated as hedges as of June 30, 2021 that are expected to be reclassified into earnings within the next 12 months is an expense of $6.0 million.
The following tables represent the items reclassified out of Accumulated other comprehensive income (loss) and the related tax effects for the three and nine months ended June 30, 2021 and 2020:
 Three Months Ended June 30
 20212020
 Amount
reclassified		Tax effectNet of taxAmount
reclassified		Tax effect Net of tax
Derivative instruments designated as hedges:
Currency exchange contracts 1
$(1.2)$0.3 $(0.9)$(1.2)$0.4 $(0.8)
Interest rate swaps 2
(4.0)1.0 (3.0)(1.7)0.4 (1.3)
Derivative instruments designated as hedges total
$(5.2)$1.3 $(3.9)$(2.9)$0.8 $(2.1)
Change in pension and postretirement defined benefit plans 3
$1.2 $(0.3)$0.9 $1.4 $(0.6)$0.8 

 Nine Months Ended June 30
 20212020
 Amount
reclassified		Tax effectNet of taxAmount
reclassified		Tax effect Net of tax
Derivative instruments designated as hedges:
Currency exchange contracts 1
$(3.0)$0.7 $(2.3)$(1.1)$0.3 $(0.8)
Interest rate swaps 2
(10.7)2.5 (8.2)(1.3)0.3 (1.0)
Derivative instruments designated as hedges total
$(13.7)$3.2 $(10.5)$(2.4)$0.6 $(1.8)
Change in pension and postretirement defined benefit plans 3
$3.7 $(0.9)$2.8 $(7.7)$1.7 $(6.0)
1 Reclassified from Accumulated other comprehensive income (loss) into Investment income (expense) and other, net.
2 Reclassified from Accumulated other comprehensive income (loss) into Interest expense.
3 Reclassified from Accumulated other comprehensive income (loss) into Cost of goods sold and Investment income (expense) and other, net. These components are included in the computation of net periodic pension expense. See Note 6. Retirement and Postretirement Benefit Plans for further information.
v3.21.2
Special Charges
 9 Months Ended
Jun. 30, 2021
Special Charges [Abstract]  
Special Charges Special Charges
Special charges are incurred in connection with various transformative initiatives, exit activities, and organizational changes to improve our business alignment and cost structure. Although these charges are infrequent and unusual in nature, additional Special charges are expected to be incurred. It is not practicable to estimate the amount of these future expected costs until such time as the evaluations are complete. The following table summarizes the Special charges recognized for the three and nine months ended June 30, 2021 and 2020.
Special ChargesThree Months Ended June 30 Nine Months Ended June 30
2021202020212020
Global information technology transformation$3.0 $6.7 $8.1 $15.3 
Workforce reduction plan0.4 — 24.0 — 
Integration-related activities2.1 2.4 7.6 9.2 
Site consolidation and other cost optimization activities, including related severance cost0.4 0.4 0.4 1.6 
Total Special Charges$5.9 $9.5 $40.1 $26.1 

Global Information Technology Transformation

In fiscal 2019, management initiated a global information technology transformation, including rationalizing and transforming our enterprise resource planning software solutions and other complementary information technology systems.

The objective of this initiative is to consolidate and streamline our key workstreams that interact with customers and vendors and support our financial reporting processes while maintaining the security of our data. The solutions designed under this initiative will be implemented over the next four to six years.

Workforce Reduction Plan

On September 15, 2020, we committed to a workforce reduction plan as part of the continued business optimization initiatives to advance our strategy and growth platforms and improve our operations and cost structure. The workforce reduction plan includes a voluntary retirement program and involuntary severance actions. For the three and nine months ended June 30, 2021, we incurred $0.4 million and $24.0 million related to this initiative within Special charges.

Integration-Related Activities

We incurred costs, including severance and benefit costs, associated with business realignment and integration activities focused on reducing complexity, increasing efficiency, and improving our cost structure. We acquired several businesses as disclosed within Note 3. Business Combinations within the 2020 Form 10-K for the fiscal year ended September 30, 2020 for which we also continue to incur integration-related costs and severance costs. 

Site Consolidation and Other Cost Optimization Activities, Including Related Severance Cost

We continue to streamline our operations and simplify our supply chain by transforming and consolidating certain manufacturing and distribution operations.

For all accrued severance and other benefit charges described above, we record reserves within Other current liabilities. The following table summarizes the reserve activity for severance and other benefits for the nine months ended June 30, 2021.

Balance as of September 30, 2020$11.3 
Expenses21.8 
Cash payments(22.0)
Reversals(0.1)
Balance as of June 30, 2021$11.0 
v3.21.2
Income Taxes
 9 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes The effective tax rate for the three months ended June 30, 2021 was 18.7% compared to 21.9% for the three months ended June 30, 2020. The rate was lower for the three months ended June 30, 2021 primarily due to lower foreign income subject to taxes in the United States compared to the three months ended June 30, 2020. The effective tax rate for the nine months ended June 30, 2021 was 18.2% compared to 17.8% for the nine months ended June 30, 2020. The rate was lower for the nine months ended June 30, 2020 primarily due to the favorable impact of excess tax benefits on deductible stock compensation compared to the nine months ended June 30, 2021. The effective tax rate for the nine months ended June 30, 2020 was also favorably impacted by the reduction of the contingent consideration accrual of $8.4 million, that was not subject to tax.
v3.21.2
Earnings per Common Share
 9 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Earnings per Common Share Earnings per Common Share
Basic earnings per share (“EPS”) is calculated based upon the weighted average number of outstanding common shares for the period, plus the effect of deferred vested shares. Diluted earnings per share is calculated consistent with the basic earnings per share calculation plus the effect of dilutive unissued common shares related to stock-based employee compensation programs. For all periods presented, anti-dilutive stock options were excluded from the calculation of diluted earnings per share. Cumulative treasury stock acquired, less cumulative shares reissued, have been excluded in determining the average number of shares outstanding.

Earnings per share are calculated as follows (share amounts in thousands):
 Three Months Ended
June 30		Nine Months Ended June 30
 2021202020212020
Net Income$49.2 $93.9 $195.1 $180.6 
Net Income per Basic Common Share$0.74 $1.41 $2.94 $2.71 
Net Income per Diluted Common Share$0.74 $1.40 $2.92 $2.68 
Average Basic Common Shares Outstanding 66,267 66,558 66,353 66,660 
Add potential effect of exercise of stock options and other unvested equity awards574 625 516 632 
Average Diluted Common Shares Outstanding 66,841 67,183 66,869 67,292 
Shares with anti-dilutive effect excluded from the computation of diluted EPS265 291 467 298 
v3.21.2
Segment Reporting
 9 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
We disclose segment information that is consistent with the way in which management operates and views the business. Our operating structure contains the following reportable segments:

•Patient Support Systems – globally provides an ecosystem of our digital and connected care solutions: devices, software, communications and integration technologies that improve care and deliver actionable insights to caregivers and patients in the acute care setting. Key products include care communications and mobility solutions, connected med-surg and ICU bed systems, sensors and surfaces, safe patient handling equipment and services.

•Front Line Care – globally provides integrated patient monitoring and diagnostic technologies – from hospital to home – that enable and support Hillrom’s connected care strategy. Our diverse portfolio includes secure, connected, digital assessment technologies to help diagnose, treat and manage a wide variety of illnesses and diseases, including respiratory therapy, cardiology, vision screening and physical assessment.
•Surgical Solutions – globally enables peak procedural performance, connectivity and video integration products that improve collaboration, workflow, safety and efficiency in the operating room, such as surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.

Our performance within each reportable segment continues to be measured on a divisional income basis before non-allocated operating and administrative costs, litigation, special charges, acquisition and integration costs, acquisition-related intangible asset amortization, and other unusual events. Divisional income generally represents the division’s gross profit, excluding acquisition-related intangible asset amortization, less its direct operating costs along with an allocation of manufacturing and distribution costs, research and development, and certain corporate functional expenses.

Non-allocated operating costs, administrative costs, and other includes functional expenses that support the entire organization such as administration, finance, legal and human resources, expenses associated with strategic developments, acquisition-related intangible asset amortization, and other events that are not indicative of operating trends. We exclude such amounts from divisional income to allow management to evaluate and understand divisional operating trends. The chief operating decision maker does not receive any asset information by reportable segment and, accordingly, we do not report asset information by reportable segment.
  Three Months Ended
June 30		 Nine Months Ended June 30
 2021202020212020
Net Revenue - United States:
Patient Support Systems$275.0 $316.9 $829.7 $872.8 
Front Line Care186.7 167.8 564.4 525.2 
Surgical Solutions39.7 22.5 109.3 97.6 
Total net revenue - United States$501.4 $507.2 $1,503.4 $1,495.6 
Net Revenue - Outside of the United States (“OUS”):
Patient Support Systems$101.1 $130.9 $322.1 $301.2 
Front Line Care79.2 84.3 256.4 239.8 
Surgical Solutions36.0 45.1 138.9 139.1 
Total net revenue - OUS$216.3 $260.3 $717.4 $680.1 
Net Revenue:    
Patient Support Systems$376.1 $447.8 $1,151.8 $1,174.0 
Front Line Care265.9 252.1 820.8 765.0 
Surgical Solutions75.7 67.6 248.2 236.7 
Total net revenue$717.7 $767.5 $2,220.8 $2,175.7 
Divisional Income:    
Patient Support Systems$74.7 $129.2 $258.0 $262.4 
Front Line Care83.4 81.1 261.1 232.5 
Surgical Solutions9.7 4.7 38.1 31.0 
Other Operating Costs:    
Non-allocated operating costs, administrative costs, and other
72.5 70.2 231.0 198.3 
Special charges5.9 9.5 40.1 26.1 
Operating Profit89.4 135.3 286.1 301.5 
Interest expense(15.7)(17.3)(50.6)(55.8)
Loss on extinguishment of debt(9.8)— (9.8)(15.6)
Investment income (expense) and other, net(3.4)2.2 12.7 (10.5)
Income Before Income Taxes$60.5 $120.2 $238.4 $219.6 
v3.21.2
Commitments and Contingencies
 9 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
General

We are subject to various claims and contingencies arising out of the normal course of business, including those relating to governmental investigations and proceedings, commercial transactions, product liability, employee related matters, antitrust, safety, health, taxes, environmental and other matters. Litigation is subject to many uncertainties and the outcome of individual litigated matters is not predictable with assurance. It is possible that some litigation matters for which reserves have not been established could be decided unfavorably to us, and that any such unfavorable decisions could have a materially adverse effect on our financial condition, results of operations and cash flows.

The Company has received a subpoena from the United States Office of Inspector General for the Department of Health and Human Services (the “DHHS”) requesting documents and information related to compliance with the False Claims Act (“FCA”) and the Anti-Kickback Statute (the “AKS”) by certain of its subsidiaries with respect to the Company’s direct to consumer business. The Company has voluntarily contacted DHHS with respect to these matters including its compliance with the FCA and the AKS. The Company is conducting an ongoing internal review and cooperating fully with the DHHS with respect to these matters.

At this stage of the inquiries, the Company is unable to predict the ultimate outcome of these matters or what impact, if any, the outcome of these matters might have on the Company's consolidated financial position, results of operations or cash flows. Violations of the FCA and AKS may result in a range of possible penalties, however, at this time, no claims have been made against the Company.

As described in Note 3. Business Combinations, on February 28, 2021, Bardy filed a complaint against Hillrom in the Court of Chancery of the State of Delaware seeking, among other things, specific performance to compel Hillrom to close the Bardy Transaction.

On July 9, 2021, the Court of Chancery of the State of Delaware ordered Hillrom to proceed with the closing of the Bardy Transaction, denying Hillrom’s claim of a "Company Material Adverse Effect". Hillrom now anticipates closing of the Bardy Transaction on or about August 6, 2021. See Note 3. Business Combinations for additional information.

Self-Insurance

We are involved in various claims, including product and general liability, workers’ compensation, auto liability and employment related matters. Such claims in the United States have deductibles and self-insured retentions at various limits up to $1.0 million per occurrence or per claim, depending upon the type of coverage and policy period. International deductibles and self-insured retentions are lower. We are also generally self-insured up to certain stop-loss limits for certain employee health benefits, including medical, drug, and dental. Our policy is to estimate reserves based upon a number of factors including known claims, estimated incurred but not reported claims and outside actuarial analysis, which are based on historical information along with certain assumptions about future events. Such estimated reserves are classified as Other current liabilities and Other long-term liabilities.
v3.21.2
Summary of Significant Accounting Policies Nature of Operations (Policies)
 9 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Recently Issued Accounting Standards
Recently Adopted Accounting Standards

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses of Financial Instruments and has subsequently issued related amendments, collectively referred to as “Topic 326”. Topic 326 requires entities to measure credit losses for financial assets measured at amortized cost based on expected losses rather than incurred losses. This adoption primarily impacted our trade accounts receivables. Under the current expected credit loss model, we review receivables for collectability based on an assessment of various factors, including historical collection experience for each receivable type and expectations of forward-looking loss estimates, and individual receivables are also reviewed for collectability based on unique circumstances. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, customer type (public or government entity versus private entity) and geographic location of the customer. We adopted ASU 2016-13 in the first quarter of fiscal 2021 using the modified retrospective transition method with a cumulative effect adjustment directly to retained earnings. The cumulative effect of applying Topic 326 was an increase to the allowance for credit losses of $3.0 million and deferred tax assets of $0.8 million with a corresponding decrease to the opening balance of Retained earnings of $2.2 million.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The purpose of the standard is to improve the overall usefulness of fair value disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. ASU 2018-13 requires the application of the prospective method of transition (for only the most recent interim or annual period presented in the initial fiscal year of adoption) to the new disclosure requirements for (1) changes in unrealized gains and losses included in other comprehensive income and (2) the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 also requires prospective application to any modifications to disclosures made because of the change to the requirements for the narrative description of measurement uncertainty. The effects of all other amendments made by ASU 2018-13 must be applied retrospectively to all periods presented. We adopted ASU 2018-13 in the first quarter of fiscal 2021. The adoption of ASU 2018-13 had no impact on our Condensed Consolidated Financial Statements.
In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. This update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement to be consistent with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). We adopted ASU 2018-15 in the first quarter of fiscal 2021 using the prospective transition method approach. The Company’s cloud computing hosting arrangements are primarily information technology agreements that support the Company’s operations and infrastructure. The adoption of ASU 2018-15 did not have a significant impact on our Condensed Consolidated Financial Statements.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606. The purpose of the standard is to (1) clarify that transactions between participants in a collaborative agreement should be accounted for under Topic 606 and (2) add unit-of-account guidance in Topic 808 to align with Topic 606. We retrospectively adopted ASU 2018-18 in the first quarter of fiscal 2021. The adoption of ASU 2018-18 had no impact on our Condensed Consolidated Financial Statements.

In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. ASU 2021- 01 is an extension of ASU 2020-04 disclosed in our 2020 Form 10-K. ASU 2021-01 clarifies the scope and guidance of Topic 848 and allows derivatives impacted by the changing of interest rates used for margin payments, discounting, or contract price alignment to qualify for certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting. ASU 2021-01 is optional and is effective for a limited period of time through December 31, 2022. As of June 30, 2021, this standard has no impact on our Condensed Consolidated Financial Statements. We will continue to monitor, assess and plan for the phase out of LIBOR.

Recently Issued Accounting Standards

In August 2018, the FASB issued ASU 2018-14, Compensation – Retirement Benefits – Defined Benefit Plans – General (Topic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans. The purpose of the standard is to improve the overall usefulness of defined benefit pension and other postretirement plan disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. ASU 2018-14 is effective for our annual disclosures for fiscal 2021 and requires a retrospective transition method. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The purpose of the standard is to remove certain exceptions to the general principles of Topic 740: Income Taxes in order to reduce the cost and complexity of its application and to maintain or improve the usefulness of the information provided to users of financial statements. ASU 2019-12 is effective for our first quarter of fiscal 2022 and will be applied either retrospectively or prospectively depending on the specific Topic 740 exception affected. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

Except as noted above, there are no significant changes to our assessment of the impact of recently issued accounting standards included in Note 1. Summary of Significant Accounting Policies of our Condensed Consolidated Financial Statements in our 2020 Form 10-K.
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation

The unaudited Condensed Consolidated Financial Statements and related notes have been prepared in accordance with the rules and regulations of the SEC for interim unaudited Condensed Consolidated Financial Statements. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete Condensed Consolidated Financial Statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying Condensed Consolidated Financial Statements to present fairly the results of the interim periods presented. Quarterly results are not necessarily indicative of annual results.

The unaudited Condensed Consolidated Financial Statements appearing in this Quarterly Report on Form 10-Q should be read in conjunction with the audited Condensed Consolidated Financial Statements and notes thereto included in Hillrom’s fiscal 2020 Form 10-K as filed with the SEC.

The Condensed Consolidated Financial Statements include the accounts of Hillrom and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

The Company makes a number of significant estimates, assumptions, and judgments in the preparation of its financial statements. Additionally, the Company measures and classifies fair value measurements in accordance with the level hierarchy in conformity with GAAP. As of June 30, 2021, the Company's significant accounting policies and estimates and valuation techniques used to measure fair value have not changed from September 30, 2020. See Note 1. Summary of Significant Accounting Policies within the 2020 Form 10-K for the fiscal year ended September 30, 2020 for further information.

Revenue Recognition — Sales and Rentals

Disaggregation of Revenue

The Company disaggregates revenue recognized from contracts with customers by geography and reportable segments consistent with the way in which management operates and views the business. See Note 11. Segment Reporting for the presentation of the Company's revenue disaggregation.

Contract Balances

Contract liabilities represent deferred revenues that arise as a result of cash received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. Such remaining performance obligations represent the portion of the contract price for which work has not been performed and are primarily related to our installation and service contracts. These contract liabilities are recorded in Deferred revenue and Other long-term liabilities. We expect to satisfy the majority of the remaining performance obligations and recognize revenue related to installation and service contracts within 12 to 24 months.
The nature of our products and services does not give rise to contract assets as we typically do not have instances where a right to payment for goods and services already transferred to a customer exists that is conditional on something other than the passage of time.

The following table summarizes contract liability activity for the nine months ended June 30, 2021. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Contract Liabilities
Balance as of September 30, 2020$138.1 
New revenue deferrals378.2 
Revenue recognized upon satisfaction of performance obligations(380.9)
Foreign currency translation adjustment0.8 
Balance as of June 30, 2021$136.2 

Rental Revenue

We make certain products available to customers under short-term lease arrangements. Rental usage of these products is provided as an alternative to product sales and is short-term in nature. Products primarily include smart beds, including, but not limited to, bariatric, intensive care unit, maternity, and home care beds, as well as surfaces. These lease arrangements provide our customers with our products during periods of peak demand or often times for specialty purposes. Additionally, we provide wearable, non-invasive ventilation products to patients covered by monthly medical insurance reimbursements, which are considered month-to-month leasing arrangements. Income arising from these lease arrangements where we are the lessor is recognized within Rental revenue. We accounted for these lease arrangements as operating leases.

Warranties and Guarantees

We routinely grant limited warranties on our products with respect to defects in material and workmanship. The terms of these warranties are generally one year; however, certain components and products have substantially longer warranty periods. We recognize a reserve with respect to these obligations at the time of product sale, with subsequent warranty claims recorded directly against the reserve. The amount of the warranty reserve is determined based on historical trend experience for the covered products. For more significant warranty-related matters, which might require a field corrective action, separate reserves are established when such events are identified and the cost of correction can be reasonably estimated.

In the normal course of business, we enter into various other guarantees and indemnities in our relationships with suppliers, service providers, customers, business partners and others. Examples of these arrangements would include guarantees of product performance, indemnifications to service providers and indemnifications of our actions to business partners. These guarantees and indemnifications have not historically had a material impact on our financial condition or results of operations, nor do we expect them to although indemnifications associated with our actions generally have no dollar limitations.

In conjunction with our acquisition and divestiture activities, we entered into select guarantees and indemnifications of performance with respect to the fulfillment of our commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. With respect to divestitures, we also routinely enter into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have an adverse impact on our Condensed Consolidated Financial Statements.
The following summarizes accrued product warranty activity for the three and nine months ended June 30, 2021.

  Three Months Ended June 30 Nine Months Ended June 30
Balance as of beginning of period$30.3 $30.8 
Provision for warranties in the period5.8 16.9 
Warranty claims in the period(6.0)(17.7)
Foreign currency translation adjustment0.1 0.2 
Balance as of end of period$30.2 $30.2 

Goodwill and Indefinite-Lived Intangible Assets

Testing for goodwill and indefinite-lived intangible asset impairment is performed annually, or on an interim basis upon the occurrence of a triggering event or change in circumstances that would more likely than not reduce the fair value of a reporting unit or indefinite-lived intangible asset below its carrying amount. The annual evaluations of goodwill and the indefinite-lived intangible asset for impairment were performed as of April 30, 2021 and did not result in any impairment.
Government Programs Related to COVID-19
On March 25, 2020, the U.S. government approved the Coronavirus Aid, Relief and Economic Security (“CARES”) Act to provide economic stimulus to address the impact of the pandemic. The governments in certain other non-U.S. countries have also approved legislation in their jurisdictions to address the impact of the pandemic. We evaluated our eligibility and assessed the conditions and requirements of participation in available programs. During the calendar year 2020, we deferred payment of the employer share of the U.S. Federal Insurance Contributions Act (“FICA”) taxes totaling $21.7 million within the Condensed Consolidated Balance Sheet, of which $10.8 million must be repaid in both December 31, 2021 and December 31, 2022, respectively, in accordance with the CARES Act within the Condensed Consolidated Balance Sheet. We continue to evaluate what impact, if any, the CARES Act, or any similar legislation in other non-U.S. jurisdictions, may have on our results of operations.
v3.21.2
Supplementary Balance Sheet Information (Tables)
 9 Months Ended
Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Supplementary Balance Sheet Information
 June 30,
2021		September 30, 2020
Inventories, net of reserves:  
Finished products$160.0 $167.6 
Work in process53.1 48.4 
Raw materials116.0 136.0 
Total inventories, net of reserves$329.1 $352.0 
Accumulated amortization of software and other intangible assets$762.6 $667.3 
Investments included in Other assets$23.7 $49.0 
Schedule of Cash Flow, Supplemental Disclosures Supplemental Cash Flow Information
Nine Months Ended
June 30
20212020
Non-cash operating activities:
Operating cash flows paid for amounts included in the measurement of lease liabilities$20.4$20.8 
Non-cash investing activities:
Change in capital expenditures not paid$(10.0)$1.8 
Sale of equity method investment— 2.1 
Non-cash consideration in exchange for asset acquisition:
Preferred securities investment25.5 — 
     Forgiveness of a prepaid performance obligation 1.8 — 
Total non-cash investing activities:$17.3 $3.9 
Non-cash financing activities:  
Distribution of shares issued under stock-based compensation plans$36.9$29.6 
Non-cash investing and financing activities:
Right of use assets obtained in exchange for new lease liabilities$7.6$14.7 
v3.21.2
Financing Agreements (Tables)
 9 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Fair Values of Long-Term Debt Instruments The estimated fair values of our long-term debt instruments are described in the table below:
 June 30,
2021		September 30, 2020
Senior unsecured 5.00% notes due on February 15, 2025
$— $310.1 
Senior unsecured 4.375% notes due on September 15, 2027
443.3 441.2 
Unsecured debentures47.2 48.0 
Total$490.5 $799.3 
The estimated fair values of our long-term unsecured debentures were based on observable inputs such as quoted prices in markets that are not active. The estimated fair values of the Senior Notes were based on quoted prices for similar liabilities. These fair value measurements were classified as Level 2.
v3.21.2
Derivatives (Tables)
 9 Months Ended
Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value
Three Months Ended
June 30		Nine Months Ended
June 30
2021202020212020
Unrealized gain (loss)$(3.0)$0.5 $(3.0)$0.5 
Realized gain (loss)0.2 (0.1)(1.0)1.1 
Fair Value

We classify fair value measurements on our derivative instruments as Level 2. The estimated fair values of our derivative instruments are described in the table below:
Derivative InstrumentsJune 30, 2021September 30, 2020Condensed Consolidated Balance Sheet Position
Interest Rate Swaps$(25.9)$(46.3)Other current liabilities
Currency Exchange Contracts(0.6)(0.4)Other current liabilities
Cross-Currency Swaps6.0 9.7 Other assets
Undesignated Forward Contracts(3.7)— Other current liabilities
Undesignated Forward Contracts0.7 — Other assets
Total$(23.5)$(37.0)
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location
v3.21.2
Retirement and Postretirement Plans (Tables)
 12 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Schedule of Components of Net Pension Expense The following table provides the components of net pension expense for our defined benefit retirement plans.
 Three Months Ended
June 30		Nine Months Ended
June 30		Condensed Consolidated Statements of Income Item
 2021202020212020
Service cost$0.5 $0.5 $1.5 $1.3 Cost of goods sold
Service cost0.8 0.9 2.4 2.5 Selling and administrative expenses
Interest cost1.8 1.9 5.5 6.8 Investment income (expense) and other, net
Expected return on plan assets(2.9)(3.4)(8.8)(10.8)Investment income (expense) and other, net
Amortization of unrecognized prior service cost, net— — — 0.1 Investment income (expense) and other, net
Amortization of net loss1.6 1.9 4.7 5.0 Investment income (expense) and other, net
Net periodic benefit cost$1.8 $1.8 $5.3 $4.9 
Special termination benefits1
— — 3.3 — Special charges
Settlement (loss) gain2
— (0.1)— 8.4 Investment income (expense) and other, net
Net pension expense$1.8 $1.7 $8.6 $13.3 
1 In September 2020, we offered certain employees in the United States the option to participate in a voluntary early retirement plan. The employees who accepted the offer received special termination benefits during the nine months ended June 30, 2021, which were recorded as a component of Special charges in the Condensed Consolidated Statements of Income. See Note 8. Special Charges for further information.
2 On March 9, 2020, we transferred pension assets totaling $40.6 million to purchase annuity contracts for a certain population of retirees with a third-party insurance company. As a result, we recognized a non-cash settlement loss of $8.4 million for the for the nine months ended June 30, 2020, which is recorded as a component of Investment income (expense) and other, net in the Condensed Consolidated Statements of Income.
v3.21.2
Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Jun. 30, 2021
Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Changes in AOCL by Component
The following tables represent the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the three months ended June 30, 2021 and 2020:
Three Months Ended June 30, 2021
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance 2
Derivative instruments designated as hedges 1:
Currency exchange contracts
$2.2 $(1.2)$1.0 $(0.3)$0.7 $(1.2)$0.7 $(0.5)
Interest rate swaps
7.4 (4.0)3.4 (0.8)2.6 (22.5)2.6 (19.9)
Cross-currency swaps
(2.7)— (2.7)0.6 (2.1)4.9 (2.1)2.8 
Derivative instruments designated as hedges total
$6.9 $(5.2)$1.7 $(0.5)$1.2 $(18.8)$1.2 $(17.6)
Foreign currency translation adjustment
11.7 — 11.7 — 11.7 (95.9)11.7 (84.2)
Change in pension and postretirement defined benefit plans
(0.1)1.2 1.1 (0.3)0.8 (38.5)0.8 (37.7)
Total$18.5 $(4.0)$14.5 $(0.8)$13.7 $(153.2)$13.7 $(139.5)


Three Months Ended June 30, 2020
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance
Derivative instruments designated as hedges 1:
Currency exchange contracts
$0.4 $(1.2)$(0.8)$0.2 $(0.6)$— $(0.6)$(0.6)
Interest rate swaps
(2.9)(1.7)(4.6)1.1 (3.5)(34.8)(3.5)(38.3)
Cross-currency swaps
(3.5)— (3.5)0.9 (2.6)16.3 (2.6)13.7 
Derivative instruments designated as hedges total
$(6.0)$(2.9)$(8.9)$2.2 $(6.7)$(18.5)$(6.7)$(25.2)
Foreign currency translation adjustment
17.1 — 17.1 — 17.1 (153.9)17.1 (136.8)
Change in pension and postretirement defined benefit plans
0.2 1.4 1.6 (0.6)1.0 (51.2)1.0 (50.2)
Total$11.3 $(1.5)$9.8 $1.6 $11.4 $(223.6)$11.4 $(212.2)
The following tables represent the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the nine months ended June 30, 2021 and 2020.
Nine Months Ended June 30, 2021
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance 2
Derivative instruments designated as hedges 1:
Currency exchange contracts
$2.8 $(3.0)$(0.2)$— $(0.2)$(0.3)$(0.2)$(0.5)
Interest rate swaps
31.2 (10.7)20.5 (4.7)15.8 (35.7)15.8 (19.9)
Cross-currency swaps
(5.0)— (5.0)1.1 (3.9)6.7 (3.9)2.8 
Derivative instruments designated as hedges total
$29.0 $(13.7)$15.3 $(3.6)$11.7 $(29.3)$11.7 $(17.6)
Foreign currency translation adjustment
26.5 — 26.5 — 26.5 (110.7)26.5 (84.2)
Change in pension and postretirement defined benefit plans
(0.3)3.7 3.4 (0.9)2.5 (40.2)2.5 (37.7)
Total$55.2 $(10.0)$45.2 $(4.5)$40.7 $(180.2)$40.7 $(139.5)

Nine Months Ended June 30, 2020
 Other comprehensive income (loss)Accumulated other comprehensive income (loss)
 Prior to
reclassification		Reclassification
from		Pre-taxTax effectNet of taxBeginning
balance		Net activity
Ending
balance
Derivative instruments designated as hedges 1:
Currency exchange contracts
$0.1 $(1.1)$(1.0)$0.2 $(0.8)$0.2 $(0.8)$(0.6)
Interest rate swaps
(41.7)(1.3)(43.0)9.9 (33.1)(5.2)(33.1)(38.3)
Cross-currency swaps
1.9 — 1.9 (0.4)1.5 12.2 1.5 13.7 
Derivative instruments designated as hedges total
$(39.7)$(2.4)$(42.1)$9.7 $(32.4)$7.2 $(32.4)$(25.2)
Foreign currency translation adjustment
8.6 — 8.6 — 8.6 (145.4)8.6 (136.8)
Change in pension and postretirement defined benefit plans
0.1 (7.7)(7.6)1.7 (5.9)(44.3)(5.9)(50.2)
Total$(31.0)$(10.1)$(41.1)$11.4 $(29.7)$(182.5)$(29.7)$(212.2)


1 See Note 5. Derivative Instruments and Hedging Activity for information regarding our hedging strategies.
2 The estimated net amount of gains and losses reported in Accumulated other comprehensive income (loss) related to our derivative instruments designated as hedges as of June 30, 2021 that are expected to be reclassified into earnings within the next 12 months is an expense of $6.0 million.
Schedule of Items Reclassified out of AOCL
The following tables represent the items reclassified out of Accumulated other comprehensive income (loss) and the related tax effects for the three and nine months ended June 30, 2021 and 2020:
 Three Months Ended June 30
 20212020
 Amount
reclassified		Tax effectNet of taxAmount
reclassified		Tax effect Net of tax
Derivative instruments designated as hedges:
Currency exchange contracts 1
$(1.2)$0.3 $(0.9)$(1.2)$0.4 $(0.8)
Interest rate swaps 2
(4.0)1.0 (3.0)(1.7)0.4 (1.3)
Derivative instruments designated as hedges total
$(5.2)$1.3 $(3.9)$(2.9)$0.8 $(2.1)
Change in pension and postretirement defined benefit plans 3
$1.2 $(0.3)$0.9 $1.4 $(0.6)$0.8 

 Nine Months Ended June 30
 20212020
 Amount
reclassified		Tax effectNet of taxAmount
reclassified		Tax effect Net of tax
Derivative instruments designated as hedges:
Currency exchange contracts 1
$(3.0)$0.7 $(2.3)$(1.1)$0.3 $(0.8)
Interest rate swaps 2
(10.7)2.5 (8.2)(1.3)0.3 (1.0)
Derivative instruments designated as hedges total
$(13.7)$3.2 $(10.5)$(2.4)$0.6 $(1.8)
Change in pension and postretirement defined benefit plans 3
$3.7 $(0.9)$2.8 $(7.7)$1.7 $(6.0)
1 Reclassified from Accumulated other comprehensive income (loss) into Investment income (expense) and other, net.
2 Reclassified from Accumulated other comprehensive income (loss) into Interest expense.
3 Reclassified from Accumulated other comprehensive income (loss) into Cost of goods sold and Investment income (expense) and other, net. These components are included in the computation of net periodic pension expense. See Note 6. Retirement and Postretirement Benefit Plans for further information.
v3.21.2
Special Charges (Tables)
 9 Months Ended
Jun. 30, 2021
Special Charges [Abstract]  
Restructuring Activity nine months ended June 30, 2021.
Balance as of September 30, 2020$11.3 
Expenses21.8 
Cash payments(22.0)
Reversals(0.1)
Balance as of June 30, 2021$11.0 
Special Charges, Net The following table summarizes the Special charges recognized for the three and nine months ended June 30, 2021 and 2020.
Special ChargesThree Months Ended June 30 Nine Months Ended June 30
2021202020212020
Global information technology transformation$3.0 $6.7 $8.1 $15.3 
Workforce reduction plan0.4 — 24.0 — 
Integration-related activities2.1 2.4 7.6 9.2 
Site consolidation and other cost optimization activities, including related severance cost0.4 0.4 0.4 1.6 
Total Special Charges$5.9 $9.5 $40.1 $26.1 
v3.21.2
Earnings per Common Share (Tables)
 9 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Calculated Earnings per Share Earnings per share are calculated as follows (share amounts in thousands):
 Three Months Ended
June 30		Nine Months Ended June 30
 2021202020212020
Net Income$49.2 $93.9 $195.1 $180.6 
Net Income per Basic Common Share$0.74 $1.41 $2.94 $2.71 
Net Income per Diluted Common Share$0.74 $1.40 $2.92 $2.68 
Average Basic Common Shares Outstanding 66,267 66,558 66,353 66,660 
Add potential effect of exercise of stock options and other unvested equity awards574 625 516 632 
Average Diluted Common Shares Outstanding 66,841 67,183 66,869 67,292 
Shares with anti-dilutive effect excluded from the computation of diluted EPS265 291 467 298 
v3.21.2
Segment Reporting (Tables)
 9 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Reconciliation of Segment Information to Consolidated Financial Information
  Three Months Ended
June 30		 Nine Months Ended June 30
 2021202020212020
Net Revenue - United States:
Patient Support Systems$275.0 $316.9 $829.7 $872.8 
Front Line Care186.7 167.8 564.4 525.2 
Surgical Solutions39.7 22.5 109.3 97.6 
Total net revenue - United States$501.4 $507.2 $1,503.4 $1,495.6 
Net Revenue - Outside of the United States (“OUS”):
Patient Support Systems$101.1 $130.9 $322.1 $301.2 
Front Line Care79.2 84.3 256.4 239.8 
Surgical Solutions36.0 45.1 138.9 139.1 
Total net revenue - OUS$216.3 $260.3 $717.4 $680.1 
Net Revenue:    
Patient Support Systems$376.1 $447.8 $1,151.8 $1,174.0 
Front Line Care265.9 252.1 820.8 765.0 
Surgical Solutions75.7 67.6 248.2 236.7 
Total net revenue$717.7 $767.5 $2,220.8 $2,175.7 
Divisional Income:    
Patient Support Systems$74.7 $129.2 $258.0 $262.4 
Front Line Care83.4 81.1 261.1 232.5 
Surgical Solutions9.7 4.7 38.1 31.0 
Other Operating Costs:    
Non-allocated operating costs, administrative costs, and other
72.5 70.2 231.0 198.3 
Special charges5.9 9.5 40.1 26.1 
Operating Profit89.4 135.3 286.1 301.5 
Interest expense(15.7)(17.3)(50.6)(55.8)
Loss on extinguishment of debt(9.8)— (9.8)(15.6)
Investment income (expense) and other, net(3.4)2.2 12.7 (10.5)
Income Before Income Taxes$60.5 $120.2 $238.4 $219.6 
v3.21.2
Summary of Significant Accounting Policies (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Mar. 31, 2021
Sep. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Selling and administrative expenses $ 215,900,000 $ 202,300,000 $ 648,600,000      
Acquisition-related intangible asset amortization     80,700,000 $ 81,300,000    
Selling and administrative expense, revised       609,000,000.0    
Cares Act 21,700,000   21,700,000      
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax 100,000   200,000      
Standard Product Warranty Accrual, Increase for Warranties Issued 5,800,000   16,900,000      
Standard Product Warranty Accrual, Decrease for Payments (6,000,000.0)   (17,700,000)      
Retained Earnings (Accumulated Deficit) 2,278,400,000   2,278,400,000     $ 2,132,200,000
Standard Product Warranty Accrual 30,200,000   30,200,000   $ 30,300,000 $ 30,800,000
Non-cash Investing Activities     17,300,000 $ 3,900,000    
Accounting Standards Update 2016-13 [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Deferred Tax Assets, Valuation Allowance 800,000   800,000      
Retained Earnings (Accumulated Deficit) 3,000,000.0   3,000,000.0      
Accounting Standards Update 2016-13 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]            
New Accounting Pronouncements or Change in Accounting Principle [Line Items]            
Retained Earnings (Accumulated Deficit) $ 2,200,000   $ 2,200,000      
v3.21.2
Summary of Significant Accounting Policies (Other Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Accounting Policies [Abstract]          
Revenues $ 717,700,000 $ 767,500,000 $ 2,220,800,000 $ 2,175,700,000  
Net Income (Loss) Attributable to Parent 49,200,000 93,900,000 195,100,000 $ 180,600,000  
Net Income $ 49,200,000 $ 93,900,000 $ 195,100,000    
Net Income Attributable to Common Shareholders per Common Share - Basic (usd per share) $ 0.74 $ 1.41 $ 2.94 $ 2.71  
Earnings Per Share, Diluted $ 0.74 $ 1.40 $ 2.92 $ 2.68  
Other Liabilities and Deferred Revenue, Noncurrent $ 136,200,000   $ 136,200,000   $ 138,100,000
Deferred Revenue, Additions 378,200,000        
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized (380,900,000)        
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ 800,000   $ 800,000    
v3.21.2
Revenue Recognition (Details) - USD ($)
 3 Months Ended
Jun. 30, 2021
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]    
Other Liabilities and Deferred Revenue, Noncurrent $ 136,200,000 $ 138,100,000
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized (380,900,000)  
Deferred Revenue 108,600,000 $ 110,100,000
Deferred Revenue, Additions 378,200,000  
Capitalized Contract Cost [Line Items]    
Deferred Revenue, Additions $ 378,200,000  
v3.21.2
Supplementary Balance Sheet Information (Details) - USD ($)
 9 Months Ended
Jan. 27, 2021
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Inventories, net of reserves:        
Finished products   $ 160,000,000.0   $ 167,600,000
Inventory, Work in Process, Gross   53,100,000   48,400,000
Inventory, Raw Materials, Net of Reserves   116,000,000.0   136,000,000.0
Total inventories, net of reserves   329,100,000   352,000,000.0
Accumulated amortization of software and other intangible assets   762.6   667,300,000
Investments   23,700,000   $ 49,000,000.0
Capital Expenditures Incurred but Not yet Paid   (10,000,000.0) $ 1,800,000  
Restricted Stock or Unit Expense   36,900,000 29,600,000  
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability   7,600,000 14,700,000  
Operating Lease, Payments   20,400,000 20,800,000  
Equity Method Investment, Realized Gain (Loss) on Disposal   0 $ 2,100,000  
EarlySense        
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination $ 25,500,000 25,500,000    
Business Combination, Consideration Transferred, Other $ 1,800,000 $ 1,800,000    
v3.21.2
Business Combinations Acquisitions (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 27, 2021
Jan. 15, 2021
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Jan. 15, 2022
Sep. 30, 2021
Sep. 30, 2020
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability         $ 8,400,000      
Payments to Acquire Businesses, Gross       $ (30,000,000.0) $ (20,600,000)      
Goodwill     $ 1,845,600,000 1,845,600,000       $ 1,835,500,000
Excel Medical                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     2,000,000.0 2,600,000        
Connecta [Member]                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration, Liability             $ 0 200,000
Videomed [Member]                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration, Liability             2,400,000 2,900,000
Bardy [Member]                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low   $ 45,000,000       $ 70,000,000    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High   57,000,000       $ 89,000,000    
Payments to Acquire Businesses, Gross   $ 375,000,000.0            
EarlySense                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 10,000,000.0              
Payments to Acquire Businesses, Gross 30,000,000.0              
Business Combination, Contingent Consideration, Liability     $ 2,400,000 2,400,000        
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination 25,500,000     25,500,000        
Business Combination, Consideration Transferred, Other 1,800,000     $ 1,800,000        
Excel [Member]                
Business Acquisition, Contingent Consideration [Line Items]                
Business Combination, Contingent Consideration, Liability             $ 1,900,000 $ 5,900,000
Developed Technology Rights [Member] | EarlySense                
Business Acquisition, Contingent Consideration [Line Items]                
Intangible Assets $ 59,400,000              
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 8 years              
v3.21.2
Business Combinations Breathe Acquisition (Details) - USD ($)
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Business Acquisition [Line Items]    
Payments to Acquire Businesses, Gross $ (30,000,000.0) $ (20,600,000)
v3.21.2
Business Combinations (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jan. 27, 2021
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Business Acquisition, Contingent Consideration [Line Items]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability       $ 8,400,000    
Securitization Program [Member]            
Business Acquisition, Contingent Consideration [Line Items]            
Revolving credit facility, matures September 2021   $ 98,300,000 $ 98,300,000     $ 82,200,000
EarlySense            
Business Acquisition, Contingent Consideration [Line Items]            
Business Combination, Consideration Transferred, Other $ 1,800,000   1,800,000      
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination 25,500,000   25,500,000      
Business Combination, Contingent Consideration, Liability   2,400,000 2,400,000      
EarlySense | Developed Technology Rights [Member]            
Business Acquisition, Contingent Consideration [Line Items]            
Intangible Assets $ 59,400,000          
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life 8 years          
Excel Medical            
Business Acquisition, Contingent Consideration [Line Items]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability   $ 2,000,000.0 $ 2,600,000      
Connecta [Member]            
Business Acquisition, Contingent Consideration [Line Items]            
Business Combination, Contingent Consideration, Liability         $ 0 $ 200,000
v3.21.2
Financing Agreements (Schedule of Total Debt) (Details) - USD ($)
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Apr. 23, 2021
Sep. 30, 2020
Oct. 07, 2019
Debt Instrument [Line Items]          
Repayments of Long-term Debt $ (37,600,000) $ (37,600,000)      
Long-term Debt, by Current and Noncurrent [Abstract]          
Unsecured debenture interest rate         4.375%
Debt Instrument, Face Amount         $ 425,000,000.0
Revolving credit facility, matures September 2021 238,400,000     $ 222,300,000  
Total Long-term debt 1,482,200,000     1,655,700,000  
Revolving Credit Facility [Member]          
Debt Instrument [Line Items]          
Letters of Credit Outstanding, Amount 10,000,000.0     9,000,000.0  
Long-term Debt, by Current and Noncurrent [Abstract]          
Revolving credit facility, matures September 2021 160,000,000.0        
Line of Credit Facility, Maximum Borrowing Capacity $ 1,030,000,000.0     1,191,000,000.0  
Senior Unsecured 5.00% Notes due on February 14, 2025 [Member]          
Long-term Debt, by Current and Noncurrent [Abstract]          
Unsecured debenture interest rate 5.00%        
Debt Instrument, Face Amount $ 300,000,000.0       $ 425.0
Securitization Program [Member]          
Long-term Debt, by Current and Noncurrent [Abstract]          
Revolving credit facility, matures September 2021 98,300,000     82,200,000  
Debt Instrument, Face Amount     $ 110,000,000.0    
Note Securitization Facility [Member]          
Long-term Debt, by Current and Noncurrent [Abstract]          
Revolving credit facility, matures September 2021 $ 90,000,000.0     $ 90,000,000.0  
Debt Instrument, Face Amount     $ 90,000,000.0    
v3.21.2
Financing Agreements (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Apr. 23, 2021
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Oct. 07, 2019
Debt Instrument [Line Items]                
Payment of long-term debt         $ (37,600,000) $ (37,600,000)    
Aggregate value of debt               $ 425,000,000.0
Unsecured debenture interest rate               4.375%
Payment for Debt Extinguishment or Debt Prepayment Cost       $ 12,200,000 (7,500,000) (12,200,000)    
Gain (Loss) on Extinguishment of Debt   $ (9,800,000) $ 0   (9,800,000) (15,600,000)    
Write off of Deferred Debt Issuance Cost   2,300,000            
Securitization Program [Member]                
Debt Instrument [Line Items]                
Debt Instrument, Term 364 days              
Revolving credit facility, matures September 2021   98,300,000     98,300,000   $ 82,200,000  
Aggregate value of debt $ 110,000,000.0              
Line of Credit Facility [Line Items]                
Revolving credit facility, matures September 2021   98,300,000     98,300,000   82,200,000  
Note Securitization Facility [Member]                
Debt Instrument [Line Items]                
Debt Instrument, Term 364 days              
Revolving credit facility, matures September 2021   90,000,000.0     90,000,000.0   90,000,000.0  
Aggregate value of debt $ 90,000,000.0              
Line of Credit Facility [Line Items]                
Revolving credit facility, matures September 2021   90,000,000.0     90,000,000.0   90,000,000.0  
Revolving Credit Facility [Member]                
Debt Instrument [Line Items]                
Senior revolving credit facility, maximum borrowing amount   1,030,000,000.0     1,030,000,000.0   1,191,000,000.0  
Revolving credit facility, matures September 2021   160,000,000.0     160,000,000.0      
Outstanding letters of credit   10,000,000.0     10,000,000.0   9,000,000.0  
Line of Credit Facility [Line Items]                
Revolving credit facility, matures September 2021   160,000,000.0     160,000,000.0      
Line of Credit Facility, Maximum Borrowing Capacity   1,030,000,000.0     1,030,000,000.0   $ 1,191,000,000.0  
Senior Unsecured 5.75% Notes due on September 1, 2023 [Member]                
Debt Instrument [Line Items]                
Payment for Debt Extinguishment or Debt Prepayment Cost           12,200,000    
Gain (Loss) on Extinguishment of Debt           15,600,000    
Write off of Deferred Debt Issuance Cost           $ 3,400,000    
Senior Unsecured 5.00% Notes due on February 14, 2025 [Member]                
Debt Instrument [Line Items]                
Aggregate value of debt   $ 300,000,000.0     $ 300,000,000.0     $ 425.0
Unsecured debenture interest rate   5.00%     5.00%      
Payment for Debt Extinguishment or Debt Prepayment Cost   $ 7,500,000            
Senior Unsecured 4.375% Notes due September 2027 [Member]                
Debt Instrument [Line Items]                
Unsecured debenture interest rate   4.375%     4.375%      
Senior Unsecured 5.75% Notes due September 2023                
Debt Instrument [Line Items]                
Unsecured debenture interest rate       575.00%        
v3.21.2
Financing Agreements (Schedule of Covenants) (Details) - USD ($)
Jun. 30, 2021
Sep. 30, 2020
Securitization Program [Member]    
Debt Instrument [Line Items]    
Revolving credit facility, matures September 2021 $ 98,300,000 $ 82,200,000
v3.21.2
Financing Agreements (Schedule of Fair Value) (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Sep. 30, 2020
Oct. 07, 2019
Debt Instrument [Line Items]      
Total $ 490.5 $ 799.3  
Unsecured debenture interest rate     4.375%
Unsecured Debentures [Member]      
Debt Instrument [Line Items]      
Fair value of unsecured notes 47.2 48.0  
Senior Unsecured 5.00% Notes due on February 14, 2025 [Member]      
Debt Instrument [Line Items]      
Fair value of unsecured notes $ 0.0 310.1  
Unsecured debenture interest rate 5.00%    
Senior Unsecured 4.375% Notes due September 2027 [Member]      
Debt Instrument [Line Items]      
Fair value of unsecured notes $ 443.3 $ 441.2  
Unsecured debenture interest rate 4.375%    
v3.21.2
Derivatives (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net $ (23.5)   $ (23.5)   $ (37,000,000.0)
Cash Flow Hedging [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net (25.9)   (25.9)   (46,300,000)
Currency Swap [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 8,100,000   8,100,000   64,400,000
Currency Swap [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net (0.6)   (0.6)    
Currency Swap [Member] | Other Current Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net         (400,000)
Not Designated as Hedging Instrument [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 236,200,000   236,200,000   169,900,000
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments (3,000,000.0) $ 500,000 (3.0) $ 500,000  
Derivative, Loss on Derivative 0.2   (1,000,000.0)    
Derivative, Gain on Derivative   $ (100,000)   $ 1,100,000  
Not Designated as Hedging Instrument [Member] | Other Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net 0.7   0.7   0
Not Designated as Hedging Instrument [Member] | Other Current Liabilities [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net (3.7)   (3.7)    
Cash Flow Hedging [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 750,000,000.0   750,000,000.0    
Net Investment Hedging [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Notional Amount 198,300,000   198,300,000    
Net Investment Hedging [Member] | Other Assets [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Derivative, Fair Value, Net 6.0   6.0   $ 9,700,000
Net Investment Hedging [Member] | Interest Expense [Member]          
Derivative Instruments, Gain (Loss) [Line Items]          
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments $ 1,300,000   $ 3,900,000    
v3.21.2
Leases (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Leases [Abstract]        
Rental expenses $ 36.6 $ 35.4 $ 110.8 $ 110.9
v3.21.2
Retirement and Postretirement Plans (Defined Benefit Plans) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Defined Benefit Plan Disclosure [Line Items]        
Interest cost $ 1,800,000 $ 1,900,000 $ 5,500,000 $ 6,800,000
Expected return on plan assets (2,900,000) (3,400,000) (8,800,000) (10,800,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit) 0 0 0 100,000
Amortization of net loss 1,600,000 1,900,000 4,700,000 5,000,000.0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement   (100,000) 3,300,000 8,400,000
Net pension expense 1,800,000 1,700,000 8,600,000 13,300,000
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan       40,600,000
Defined contribution savings plans expense 7,300,000 7,300,000 23,100,000 23,600,000
Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits     200,000  
Cost of Goods and Service Benchmark [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 500,000 500,000 1,500,000 1,300,000
Selling, General and Administrative Expenses [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Service cost $ 800,000 $ 900,000 $ 2,400,000 $ 2,500,000
v3.21.2
Retirement and Postretirement Plans (Defined Contribution Plans) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Retirement Benefits [Abstract]        
Defined contribution savings plans expense $ 7.3 $ 7.3 $ 23.1 $ 23.6
v3.21.2
Other Comprehensive Income (Loss) (Schedule of Changes in AOCL by Component) (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net $ 6,000,000.0        
Other comprehensive income (loss)          
Other Comprehensive Income (Loss), Net of Tax, Total 13,700,000 $ 11,400,000 $ 40,700,000 $ (29,700,000) $ (29,700,000)
Accumulated other comprehensive loss          
Beginning balance     1,726,100,000    
Net activity 13,700,000 11,400,000 40,700,000 (29,700,000) (29,700,000)
Ending balance 1,821,000,000.0   1,821,000,000.0   1,726,100,000
Income Tax Expense (Benefit) 11,300,000 26,300,000 43,300,000 39,000,000.0  
Net Income (Loss) Attributable to Parent 49,200,000 93,900,000 195,100,000 180,600,000  
Available-for-sale Securities and Hedges [Member]          
Other comprehensive income (loss)          
Prior to reclassification 6,900,000 (6,000,000.0) 29,000,000.0 (39,700,000)  
Reclassification from 5,200,000 (2,900,000) (13,700,000) (2,400,000)  
Pre-tax 1,700,000 (8,900,000) 15,300,000 (42,100,000)  
Tax effect 500,000 2,200,000 (3,600,000) 9,700,000  
Other Comprehensive Income (Loss), Net of Tax, Total 1,200,000 (6,700,000) 11,700,000 (32,400,000)  
Accumulated other comprehensive loss          
Beginning balance (18,800,000) (18,500,000) (29,300,000) 7,200,000 7,200,000
Net activity 1,200,000 (6,700,000) 11,700,000 (32,400,000)  
Ending balance (17,600,000) (25,200,000) (17,600,000) (25,200,000) (29,300,000)
Net Income (Loss) Attributable to Parent (3,900,000) (2,100,000) (10,500,000) (1,800,000)  
Foreign Currency Translation Adjustment [Member]          
Other comprehensive income (loss)          
Prior to reclassification 11,700,000 17,100,000 26,500,000 8,600,000  
Reclassification from 0 0 0 0  
Pre-tax 11,700,000 17,100,000 26,500,000 8,600,000  
Tax effect 0 0 0 0  
Other Comprehensive Income (Loss), Net of Tax, Total 11,700,000 17,100,000 26,500,000 8,600,000  
Accumulated other comprehensive loss          
Beginning balance (95,900,000) (153,900,000) (110,700,000) (145,400,000) (145,400,000)
Net activity 11,700,000 17,100,000 26,500,000 8,600,000  
Ending balance (84,200,000) (136,800,000) (84,200,000) (136,800,000) (110,700,000)
Change in Pension and Postretirement Defined Benefit Plans [Member]          
Other comprehensive income (loss)          
Prior to reclassification (100,000) 200,000 (300,000) 100,000  
Reclassification from 1,200,000 1,400,000 3,700,000 (7,700,000)  
Pre-tax 1,100,000 1,600,000 3,400,000 (7,600,000)  
Tax effect (300,000) (600,000) (900,000) 1,700,000  
Other Comprehensive Income (Loss), Net of Tax, Total 800,000 1,000,000.0 2,500,000 (5,900,000)  
Accumulated other comprehensive loss          
Beginning balance (38,500,000) (51,200,000) (40,200,000) (44,300,000) (44,300,000)
Net activity 800,000 1,000,000.0 2,500,000 (5,900,000)  
Ending balance (37,700,000) (50,200,000) (37,700,000) (50,200,000) (40,200,000)
Income Tax Expense (Benefit) (300,000) (600,000) (900,000) 1,700,000  
Change in Pension and Postretirement Defined Benefit Plans [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]          
Accumulated other comprehensive loss          
Net Income (Loss) Attributable to Parent 900,000 (800,000) 2,800,000 (6,000,000.0)  
Accumulated Other Comprehensive Income (Loss) [Member]          
Other comprehensive income (loss)          
Prior to reclassification 18,500,000 11,300,000 55,200,000 (31,000,000.0)  
Reclassification from (4,000,000.0) (1,500,000) 10,000,000.0 (10,100,000)  
Pre-tax 14,500,000 9,800,000 45,200,000 (41,100,000)  
Tax effect (800,000) 1,600,000 (4,500,000) 11,400,000  
Other Comprehensive Income (Loss), Net of Tax, Total 13,700,000 11,400,000 40,700,000 (29,700,000)  
Accumulated other comprehensive loss          
Beginning balance (153,200,000) (223,600,000) (180,200,000) (182,500,000) (182,500,000)
Net activity 13,700,000 11,400,000 40,700,000 (29,700,000)  
Ending balance (139,500,000) (212,200,000) (139,500,000) (212,200,000) (180,200,000)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent          
Other comprehensive income (loss)          
Reclassification from (5,200,000) (2,900,000) (13,700,000) (2,400,000)  
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent | Reclassification out of Accumulated Other Comprehensive Income [Member]          
Accumulated other comprehensive loss          
Income Tax Expense (Benefit) 1,300,000 800,000 3,200,000 600,000  
Foreign Exchange Forward [Member] | Available-for-sale Securities and Hedges [Member]          
Other comprehensive income (loss)          
Pre-tax 1,000,000.0 (800,000) (200,000) (1,000,000.0)  
Other Comprehensive Income (Loss), Net of Tax, Total 700,000 (600,000) (200,000) (800,000)  
Accumulated other comprehensive loss          
Beginning balance (1,200,000) 0 (300,000) 200,000 200,000
Net activity 700,000 (600,000) (200,000) (800,000)  
Ending balance (500,000) (600,000) (500,000) (600,000) (300,000)
Foreign Exchange Forward [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent          
Other comprehensive income (loss)          
Tax effect (300,000) 200,000 0 200,000  
Interest Rate Swap [Member] | Available-for-sale Securities and Hedges [Member]          
Other comprehensive income (loss)          
Pre-tax 3,400,000 (4,600,000) 20,500,000 (43,000,000.0)  
Other Comprehensive Income (Loss), Net of Tax, Total 2,600,000 (3,500,000) 15,800,000 (33,100,000)  
Accumulated other comprehensive loss          
Beginning balance (22,500,000) (34,800,000) (35,700,000) (5,200,000) (5,200,000)
Net activity 2,600,000 (3,500,000) 15,800,000 (33,100,000)  
Ending balance (19,900,000) (38,300,000) (19,900,000) (38,300,000) (35,700,000)
Interest Rate Swap [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent          
Other comprehensive income (loss)          
Prior to reclassification 7,400,000 (2,900,000) 31,200,000 (41,700,000)  
Reclassification from (4,000,000.0) (1,700,000) (10,700,000) (1,300,000)  
Tax effect (800,000) 1,100,000 (4,700,000) 9,900,000  
Accumulated other comprehensive loss          
Income Tax Expense (Benefit) 1,000,000.0 400,000 2,500,000 300,000  
Net Income (Loss) Attributable to Parent (3,000,000.0) (1,300,000) (8,200,000) (1,000,000.0)  
Currency Swap [Member] | Available-for-sale Securities and Hedges [Member]          
Accumulated other comprehensive loss          
Beginning balance 4,900,000 16,300,000 6,700,000 12,200,000 12,200,000
Ending balance         $ 6,700,000
Currency Swap [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent          
Other comprehensive income (loss)          
Prior to reclassification (2,700,000) (3,500,000) (5,000,000.0) 1,900,000  
Reclassification from 0 0 0 0  
Tax effect 600,000 900,000 1,100,000 (400,000)  
Foreign Exchange Contract [Member] | Available-for-sale Securities and Hedges [Member]          
Other comprehensive income (loss)          
Pre-tax (2,700,000) (3,500,000) (5,000,000.0) 1,900,000  
Other Comprehensive Income (Loss), Net of Tax, Total (2,100,000) (2,600,000) (3,900,000) 1,500,000  
Accumulated other comprehensive loss          
Net activity (2,100,000) (2,600,000) (3,900,000) 1,500,000  
Ending balance 2,800,000 13,700,000 2,800,000 13,700,000  
Foreign Exchange | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent          
Other comprehensive income (loss)          
Prior to reclassification 2,200,000 400,000 2,800,000 100,000  
Reclassification from (1,200,000) (1,200,000) (3,000,000.0) (1,100,000)  
Accumulated other comprehensive loss          
Income Tax Expense (Benefit) 300,000 400,000 700,000 300,000  
Net Income (Loss) Attributable to Parent $ (900,000) $ (800,000) $ (2,300,000) $ (800,000)  
v3.21.2
Other Comprehensive Income (Loss) (Schedule of Items Reclassified out of AOCL) (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Mar. 31, 2021
Mar. 31, 2020
Sep. 30, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Amount reclassified $ (60,500,000) $ (60,500,000) $ (120,200,000) $ (120,200,000) $ (238,400,000) $ (219,600,000) $ (238,400,000) $ (219,600,000)      
Tax effect   11,300,000   26,300,000 43,300,000 39,000,000.0          
Net of tax   49,200,000   93,900,000 195,100,000 180,600,000          
Net activity   13,700,000   11,400,000 40,700,000 (29,700,000)   (29,700,000)      
Stockholders' Equity Attributable to Parent   1,821,000,000.0 1,726,100,000   1,821,000,000.0     1,726,100,000      
Available-for-sale Securities and Hedges [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   5,200,000   (2,900,000) (13,700,000) (2,400,000)          
Net of tax   (3,900,000)   (2,100,000) (10,500,000) (1,800,000)          
Prior to reclassification   6,900,000   (6,000,000.0) 29,000,000.0 (39,700,000)          
Other Comprehensive Income (Loss), before Tax   1,700,000   (8,900,000) 15,300,000 (42,100,000)          
Other Comprehensive Income (Loss), Tax   500,000   2,200,000 (3,600,000) 9,700,000          
Net activity   1,200,000   (6,700,000) 11,700,000 (32,400,000)          
Stockholders' Equity Attributable to Parent   (17,600,000) (29,300,000) (25,200,000) (17,600,000) (25,200,000)   (29,300,000) $ (18,800,000) $ (18,500,000) $ 7,200,000
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   0   0 0 0          
Prior to reclassification   11,700,000   17,100,000 26,500,000 8,600,000          
Other Comprehensive Income (Loss), before Tax   11,700,000   17,100,000 26,500,000 8,600,000          
Other Comprehensive Income (Loss), Tax   0   0 0 0          
Net activity   11,700,000   17,100,000 26,500,000 8,600,000          
Stockholders' Equity Attributable to Parent   (84,200,000) (110,700,000) (136,800,000) (84,200,000) (136,800,000)   (110,700,000) (95,900,000) (153,900,000) (145,400,000)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   1,200,000   1,400,000 3,700,000 (7,700,000)          
Tax effect   (300,000)   (600,000) (900,000) 1,700,000          
Prior to reclassification   (100,000)   200,000 (300,000) 100,000          
Other Comprehensive Income (Loss), before Tax   1,100,000   1,600,000 3,400,000 (7,600,000)          
Other Comprehensive Income (Loss), Tax   (300,000)   (600,000) (900,000) 1,700,000          
Net activity   800,000   1,000,000.0 2,500,000 (5,900,000)          
Stockholders' Equity Attributable to Parent   (37,700,000) (40,200,000) (50,200,000) (37,700,000) (50,200,000)   (40,200,000) (38,500,000) (51,200,000) (44,300,000)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   (5,200,000)   (2,900,000) (13,700,000) (2,400,000)          
Accumulated Other Comprehensive Income (Loss) [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   (4,000,000.0)   (1,500,000) 10,000,000.0 (10,100,000)          
Prior to reclassification   18,500,000   11,300,000 55,200,000 (31,000,000.0)          
Other Comprehensive Income (Loss), before Tax   14,500,000   9,800,000 45,200,000 (41,100,000)          
Other Comprehensive Income (Loss), Tax   (800,000)   1,600,000 (4,500,000) 11,400,000          
Net activity   13,700,000   11,400,000 40,700,000 (29,700,000)          
Stockholders' Equity Attributable to Parent   (139,500,000) (180,200,000) (212,200,000) (139,500,000) (212,200,000)   (180,200,000) (153,200,000) (223,600,000) (182,500,000)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Net of tax   900,000   (800,000) 2,800,000 (6,000,000.0)          
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Tax effect   1,300,000   800,000 3,200,000 600,000          
Foreign Exchange Forward [Member] | Available-for-sale Securities and Hedges [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Other Comprehensive Income (Loss), before Tax   1,000,000.0   (800,000) (200,000) (1,000,000.0)          
Net activity   700,000   (600,000) (200,000) (800,000)          
Stockholders' Equity Attributable to Parent   (500,000) (300,000) (600,000) (500,000) (600,000)   (300,000) (1,200,000) 0 200,000
Foreign Exchange Forward [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Other Comprehensive Income (Loss), Tax   (300,000)   200,000 0 200,000          
Interest Rate Swap [Member] | Available-for-sale Securities and Hedges [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Other Comprehensive Income (Loss), before Tax   3,400,000   (4,600,000) 20,500,000 (43,000,000.0)          
Net activity   2,600,000   (3,500,000) 15,800,000 (33,100,000)          
Stockholders' Equity Attributable to Parent   (19,900,000) (35,700,000) (38,300,000) (19,900,000) (38,300,000)   (35,700,000) (22,500,000) (34,800,000) (5,200,000)
Interest Rate Swap [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   (4,000,000.0)   (1,700,000) (10,700,000) (1,300,000)          
Tax effect   1,000,000.0   400,000 2,500,000 300,000          
Net of tax   (3,000,000.0)   (1,300,000) (8,200,000) (1,000,000.0)          
Prior to reclassification   7,400,000   (2,900,000) 31,200,000 (41,700,000)          
Other Comprehensive Income (Loss), Tax   (800,000)   1,100,000 (4,700,000) 9,900,000          
Foreign Exchange | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   (1,200,000)   (1,200,000) (3,000,000.0) (1,100,000)          
Tax effect   300,000   400,000 700,000 300,000          
Net of tax   (900,000)   (800,000) (2,300,000) (800,000)          
Prior to reclassification   2,200,000   400,000 2,800,000 100,000          
Currency Swap [Member] | Available-for-sale Securities and Hedges [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Stockholders' Equity Attributable to Parent     $ 6,700,000         $ 6,700,000 $ 4,900,000 $ 16,300,000 $ 12,200,000
Currency Swap [Member] | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax   0   0 0 0          
Prior to reclassification   (2,700,000)   (3,500,000) (5,000,000.0) 1,900,000          
Other Comprehensive Income (Loss), Tax   600,000   900,000 1,100,000 (400,000)          
Foreign Exchange Contract [Member] | Available-for-sale Securities and Hedges [Member]                      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]                      
Other Comprehensive Income (Loss), before Tax   (2,700,000)   (3,500,000) (5,000,000.0) 1,900,000          
Net activity   (2,100,000)   (2,600,000) (3,900,000) 1,500,000          
Stockholders' Equity Attributable to Parent   $ 2,800,000   $ 13,700,000 $ 2,800,000 $ 13,700,000          
v3.21.2
Special Charges (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]        
Special charges $ 5.9 $ 9.5 $ 40.1 $ 26.1
Restructuring charges     21.8  
Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges 2.1 2.4 7.6 9.2
Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges 0.4 0.0    
Site Consolidation [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges 0.4 0.4 0.4 1.6
Business Optimization [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges     8.1 15.3
Business Optimization [Member] | Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges     $ 24.0 $ 0.0
Global Restructuring Program [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges $ 3.0 $ 6.7    
v3.21.2
Special Charges (Schedule of Restructuring Activity) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Restructuring Cost and Reserve [Line Items]        
Beginning Balance     $ 11.3  
Expenses     21.8  
Cash payments     (22.0)  
Restructuring Reserve, Accrual Adjustment     (0.1)  
Ending Balance $ 11.0   11.0  
Special charges 5.9 $ 9.5 40.1 $ 26.1
Global Restructuring Program [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges 3.0 6.7    
Business Optimization [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges     8.1 15.3
Other Restructuring [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges 2.1 2.4 7.6 9.2
Employee Severance [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges $ 0.4 $ 0.0    
Employee Severance [Member] | Business Optimization [Member]        
Restructuring Cost and Reserve [Line Items]        
Special charges     $ 24.0 $ 0.0
v3.21.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Effective tax rate 18.70% 21.90% 18.20% 17.80%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability       $ 8.4
v3.21.2
Earnings per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2020
Earnings Per Share [Abstract]          
Net Income (Loss) Attributable to Parent $ 49,200,000 $ 93,900,000 $ 195,100,000 $ 180,600,000  
Net income attributable to common shareholders per common share - Basic (usd per share) $ 0.74 $ 1.41 $ 2.94 $ 2.71  
Net income attributable to common shareholders per common share - Diluted (usd per share) $ 0.74 $ 1.40 $ 2.92 $ 2.68  
Average Common Shares Outstanding - Basic (in shares) 66,267 66,558 66,353 66,660  
Add potential effect of exercise of stock options and other unvested equity awards (in shares) 574 625 516 632  
Average shares outstanding - Diluted (in shares) 66,841 67,183 66,869 67,292  
Shares with anti-dilutive effect excluded from the computation of Diluted EPS (in shares) 265   467 298 291
v3.21.2
Common Stock (Details) - USD ($)
$ in Millions
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Class of Stock Disclosures [Abstract]    
Share-based Payment Arrangement, Noncash Expense $ 32.7 $ 27.2
v3.21.2
Common Stock Common Stock (Share Repurchase Program) (Details) - USD ($)
 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Equity, Class of Treasury Stock [Line Items]    
Payments for Repurchase of Common Stock $ (130,700,000) $ (54,100,000)
v3.21.2
Common Stock Common Stock (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Payment, Tax Withholding, Share-based Payment Arrangement $ (800,000) $ (600,000) $ (9,300,000) $ (16,400,000)
Payments for Repurchase of Common Stock     $ (130,700,000) $ (54,100,000)
v3.21.2
Guarantees (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]    
Balance at beginning of period $ 30.3 $ 30.8
Standard Product Warranty Accrual, Increase for Warranties Issued 5.8 16.9
Standard Product Warranty Accrual, Decrease for Payments 6.0 17.7
Balance at end of period $ 30.2 $ 30.2
v3.21.2
Segment Reporting (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]                
Revenues   $ 717,700,000   $ 767,500,000 $ 2,220,800,000 $ 2,175,700,000    
Special charges   5,900,000   9,500,000 40,100,000 26,100,000    
Operating profit $ 89,400,000 89,400,000 $ 135,300,000 135,300,000 286,100,000 301,500,000 $ 286,100,000 $ 301,500,000
Interest expense   (15,700,000)   (17,300,000) (50,600,000) (55,800,000)    
Gain (Loss) on Extinguishment of Debt   (9,800,000)   0 (9,800,000) (15,600,000)    
Investment income (expense) and other, net   (3,400,000)   2,200,000 12,700,000 (10,500,000)    
Income Before Income Taxes 60,500,000 $ 60,500,000 120,200,000 $ 120,200,000 $ 238,400,000 $ 219,600,000 238,400,000 219,600,000
Corporate and Other [Member]                
Segment Reporting Information [Line Items]                
Non-allocated operating costs, administrative and other 72,500,000   70,200,000       231,000,000.0 198,300,000
Operating Segments [Member]                
Segment Reporting Information [Line Items]                
Revenues 717,700,000   767,500,000       2,220,800,000 2,175,700,000
Operating Segments [Member] | Patient Support Systems [Member]                
Segment Reporting Information [Line Items]                
Revenues 376,100,000   447,800,000       1,151,800,000 1,174,000,000.0
Divisional Income 74,700,000   129,200,000       258,000,000.0 262,400,000
Operating Segments [Member] | Front Line Care [Member]                
Segment Reporting Information [Line Items]                
Revenues 265,900,000   252,100,000       820,800,000 765,000,000.0
Divisional Income 83,400,000   81,100,000       261,100,000 232,500,000
Operating Segments [Member] | Surgical Solutions [Member]                
Segment Reporting Information [Line Items]                
Revenues 75,700,000   67,600,000       248,200,000 236,700,000
Divisional Income 9,700,000   4,700,000       38,100,000 31,000,000.0
Geographic Distribution, Domestic [Member] | Operating Segments [Member]                
Segment Reporting Information [Line Items]                
Revenues 501,400,000   507,200,000       1,503,400,000 1,495,600,000
Geographic Distribution, Domestic [Member] | Operating Segments [Member] | Patient Support Systems [Member]                
Segment Reporting Information [Line Items]                
Revenues 275,000,000.0   316,900,000       829,700,000 872,800,000
Geographic Distribution, Domestic [Member] | Operating Segments [Member] | Front Line Care [Member]                
Segment Reporting Information [Line Items]                
Revenues 186,700,000   167,800,000       564,400,000 525,200,000
Geographic Distribution, Domestic [Member] | Operating Segments [Member] | Surgical Solutions [Member]                
Segment Reporting Information [Line Items]                
Revenues 39,700,000   22,500,000       109,300,000 97,600,000
Non-US [Member] | Operating Segments [Member]                
Segment Reporting Information [Line Items]                
Revenues 216,300,000   260,300,000       717,400,000 680,100,000
Non-US [Member] | Operating Segments [Member] | Patient Support Systems [Member]                
Segment Reporting Information [Line Items]                
Revenues 101,100,000   130,900,000       322,100,000 301,200,000
Non-US [Member] | Operating Segments [Member] | Front Line Care [Member]                
Segment Reporting Information [Line Items]                
Revenues 79,200,000   84,300,000       256,400,000 239,800,000
Non-US [Member] | Operating Segments [Member] | Surgical Solutions [Member]                
Segment Reporting Information [Line Items]                
Revenues $ 36,000,000.0   $ 45,100,000       $ 138,900,000 $ 139,100,000
v3.21.2
Commitments and Contingencies (Details)
$ in Millions
Sep. 30, 2021
USD ($)
Uninsured Risk [Member] | Maximum [Member]  
Loss Contingencies [Line Items]  
Deductibles and self-insured retentions $ 1.0
v3.21.2
Label Element Value
Retained Earnings [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 1,967,400,000
Additional Paid-in Capital [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 637,400,000
Common Stock [Member]  
Common Stock, Shares, Outstanding us-gaap_CommonStockSharesOutstanding 88,457,634
Retained Earnings [Member] | Previously Reported [Member]  
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest $ 300,000